TW200815042A - Cosmetic preparation containing dimer dilinoleic acid diethylene glycol oligomer ester - Google Patents

Cosmetic preparation containing dimer dilinoleic acid diethylene glycol oligomer ester Download PDF

Info

Publication number
TW200815042A
TW200815042A TW096112802A TW96112802A TW200815042A TW 200815042 A TW200815042 A TW 200815042A TW 096112802 A TW096112802 A TW 096112802A TW 96112802 A TW96112802 A TW 96112802A TW 200815042 A TW200815042 A TW 200815042A
Authority
TW
Taiwan
Prior art keywords
cream
linoleic acid
diethylene glycol
skin
acid
Prior art date
Application number
TW096112802A
Other languages
Chinese (zh)
Other versions
TWI392518B (en
Inventor
Tamie Suzuki
Shoko Matsukuma
Takashi Yoshino
Yukihiro Ohashi
Original Assignee
Fancl Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fancl Corp filed Critical Fancl Corp
Publication of TW200815042A publication Critical patent/TW200815042A/en
Application granted granted Critical
Publication of TWI392518B publication Critical patent/TWI392518B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36Carboxylic acids; Salts or anhydrides thereof
    • A61K8/361Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/39Derivatives containing from 2 to 10 oxyalkylene groups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/84Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
    • A61K8/86Polyethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/005Preparations for sensitive skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74Biological properties of particular ingredients
    • A61K2800/75Anti-irritant

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Cosmetics (AREA)

Abstract

Disclosed is a cosmetic preparation having excellent irritation reducing effects, which contains a dimer dilinoleic acid diethylene glycol oligomer ester.

Description

200815042 九、發明說明: 【發明所屬之技術領域】 本發明係有關一種含有二聚亞油酸二乙二醇酯寡聚物(dimer dilinoleate diethylene giycol olig〇mer eSter)的化妝料。 【先前技術】 近年來隨著環境的㈣,患有所職錄皮膚炎等過敏疾病 患者,或者有皮膚過敏的人逐漸增加,由於這些人的皮膚容易過 敏’經常會出現由化妝品等物品所引起的發紅、發癢等症狀,而 需求比較低刺激的化妝&,因此市面上需要提供一種全新、對緩 和這類刺激具優異效果的成分。200815042 IX. DESCRIPTION OF THE INVENTION: TECHNICAL FIELD The present invention relates to a cosmetic containing dimer dilinoleate diethylene giycol olig〇mer eSter. [Prior Art] In recent years, with the environment (4), patients with allergic diseases such as dermatitis, or people with skin allergies gradually increase, because these people's skin is easily allergic 'often caused by cosmetics and other items The redness, itching and other symptoms, and the demand for less stimulating makeup &, the market needs to provide a new, excellent ingredients to alleviate these stimuli.

、已揭示有如海滞糖單體脂肪酸酯(專利文獻1 :特開平 1〇—45560號公報)、擁有全氟燒基及聚氧化烯⑽輝lkylene〕 為支鏈的销脂(專利文獻2:特開平卜i99629號公報),作為 =舌性劑等的皮膚刺激緩和劑;如苯乙基1—配糖物、苯乙 =配糖物等的葡萄糖衍生物(專利文獻3:特開平8—咖 報)’作為乙醇刺激緩和劑;& 纖W補文獻4 :特開平 酸三絲、錄⑽Mi _關雜和财;如檸檬 作為皮膚外用特開平卜麵號公報), 極大比例_,雖° ’襲錄絲劑中财 雖已有.絲全性的研究(料敝獻1:杉 山、太田、「化妝品她顯的錢 叢書、日本«皮膚衛生協會、1999年2^、日本皮膚= ―142),但卻尚未有針對其刺激緩和作用來進二41卷、p 關於合右-取 _用笊進仃研究。 麵^ 化妝料’曾在議獻6 (特開靡 軸嫩♦恤、觸感、對皮It has been disclosed that a fatty acid ester of a staghorn sugar monomer (Patent Document 1: JP-A No. Hei. No. 45560), a pin ester having a perfluoroalkyl group and a polyoxyalkylene (10) fluorene is disclosed (Patent Document 2) (Japanese Unexamined Patent Publication No. No. No. No. No. No. No. No. No. No. No. No. No. No. No. No. No. No. No. No. No. No. No. No. No. No. No. No. No. No. No. No. No. No. No. No. No. No. No. No. No. No. No. No. No. No. No. No. No. No. No. No. No. No. No. No. No. No. No. No. No. No. No. No. No. No. No. No. No. No. No. No. No. No. No. No. No. No. No. No. No. No. No. No. No. No. No. No. No. No. No. No -Café) 'As an ethanol-stimulated tempering agent; & Fiber W Supplementary Literature 4: Tetra-flattenedic acid tri-filament, recorded (10) Mi _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ Although the 'Inscription of Silk Recordings' in the fortune has been studied in silk. (Materials 1: Sugiyama, Ota, "Cosmetics, her money series, Japan «Skin Health Association, 1999 2^, Japanese skin = ― 142), but there has not been a tempering effect to enter the second 41 volumes, p about the right-to-take _ using 笊 仃 research. Face ^ cosmetics 'has been in the offer 6 (special open shaft tender shirt, Tactile, opposite

:而在Li I〖生、提而觸感的持續性,以及毛髮的易整理性。 A:專_6+ ’並沒有糊予以討論。 【專利文獻1】特開平1〇一4556〇號公報 【專利文獻2】特開平6-199629號公報 【專利文獻3】特開平8-283121號公報 【專利文獻4】特開平2〇〇2 — 212024號公報 【專利文獻5】特開平5—255118號公報 【專利文獻6】特開2〇〇4—277285號公報: In Li I, the persistence of the touch, and the ease of finishing the hair. A: There is no ambiguity to discuss _6+ ’. [Patent Document 1] Japanese Laid-Open Patent Publication No. Hei No. Hei. No. Hei. No. Hei. No. Hei. [Patent Document 5] JP-A-H05-255118 (Patent Document 6)

【非專利文獻1】杉山、太田、「化妝品油性原料的皮膚刺激性評 價」、曰本皮膚協會叢書、曰本產業皮膚衛生協會、1999年2月、 第 41 卷、ρ· 136-142 【發明内容】 本發明之目的是找出一種刺激緩和作用優異的油劑,進而提 供含有該油劑的化妝料。 本發明的主要構成如下: 200815042 (1) 一種含有一聚亞油酸二乙二醇酯寡聚物的化妝料。 (2) 如(1)之化妝料,其二聚亞油酸二乙二醇酯寡聚物中, 構成之二聚亞油酸及二乙二醇的比例為,二聚亞油酸··二乙二醇 —0· 5莫耳· 1· 〇莫耳〜〇· 8莫耳:1· 〇莫耳。 (3) 如⑴之化妝料’其二聚亞油酸二乙二醇酯寡聚物中, 構成之二聚亞油酸及二乙二醇的比例為,二聚亞油酸:二乙二醇 = 0.5莫耳:1.0莫耳。 (4) 如⑴之化妝料,其二聚亞油酸二乙二醇酯寡聚物在沾 °C中的黏度為2, 500〜4, 500mpa · s。 (5) 如(1)〜(4)任一項之化妝料,其二聚亞油酸二乙二醇酯 寡聚物是一種皮膚刺激緩和成分。 曰 (6) 如(1)〜(5)任一項之化妝料,其為臉部用或身體 濕化妝料。 之保[Non-Patent Document 1] Sugiyama and Ota, "Skin Irritability Evaluation of Cosmetic Oily Raw Materials", Sakamoto Skin Association Series, Sakamoto Industrial Skin Hygiene Association, February 1999, Vol. 41, ρ·136-142 [Invention Contents The object of the present invention is to find an oil agent which is excellent in stimulating and relaxing, and further provides a cosmetic containing the oil. The main constitution of the present invention is as follows: 200815042 (1) A cosmetic containing a poly(ethylene phthalate) oligomer. (2) In the cosmetic material of (1), the ratio of dimerized linoleic acid and diethylene glycol in the dimerized linoleic acid diethylene glycol oligomer is dimerized linoleic acid·· Diethylene glycol - 0 · 5 Mo · 1 · 〇 Mo Er ~ 〇 · 8 Mo Er: 1 · 〇 Mo Er. (3) In the cosmetic material of (1), the ratio of dimerized linoleic acid and diethylene glycol in the dimerized linoleic acid diethylene glycol oligomer is dimerized linoleic acid: diethylene Alcohol = 0.5 mole: 1.0 mole. (4) The cosmetic material of (1) has a dimerized linoleic acid diethylene glycol oligomer having a viscosity of 2,500 to 4,500 mPa·s in a °C. (5) The cosmetic material of any one of (1) to (4), wherein the dimerized linoleic acid diethylene glycol ester oligomer is a skin irritation mitigating component. 6 (6) A cosmetic according to any one of (1) to (5), which is a facial or body moisturizing cosmetic. Protection

(7) 如(2)〜(6)任一項之化妝料,其含有5〜2〇質量%、一 聚亞油酸二乙二醇酯寡聚物。 里〇的一 (8) -種含有二聚亞油酸二乙二醇酯寡聚物的化妝 劑,其構成之二聚亞油酸與二乙二醇的比例為,二聚亞、、由/ /由 乙二醇=Q· 5莫耳·· U莫耳〜G_ 8莫耳·· 1· G莫耳。^ ·— 根據本發明,可達到以下之效果。 乂及3有該油劑 1·可以提供一種刺激緩和效果優越的油劑 的化妝料。 7 200815042 2·由於本發明的化妝料翻激緩和效果優越,因此可以藉由 使用本發明之化妝料,來抑制關激物㈣皮膚所造成的隔離破 裹又藉由抑制隔離破壞來改善肌膚的粗糙,同時保護皮膚, 因此可以提供’肌膚粗糙改善效果、健效果優異之化妝料。 3·藉由使用本發明的化妝料,對於伴隨皮膚刺激而來的乾燥 所引起的老化現象,能藉由優異的保濕效果來維持皮膚健康,因 此可以預防老化。 4·由於本發明之化妝料所使用的二聚亞油酸二乙二醇酯寡聚 物的黏性不高,黏腻感以及眩光感不強,所以很適合使用在乳液、 乳霜等保濕用化妝料上。 【實施方式】 以下,將詳細說明本發明。 本發明之二聚亞油酸二乙二醇酯寡聚物,係將二聚亞油酸與 二乙二醇酯化後所得。 <二聚亞油酸> 二聚亞油酸係以一般稱為二聚酸的2元酸(dibasic acid), 將2分子的亞麻油酸[(9Z,12Z)-十八碳-9,12-二烯酸]等不飽和脂 肪酸聚合後之亞麻油酸的2聚物。在亞麻油酸聚合反應的生成物 之中,除了亞麻油酸的2聚物以外,也包含未反應的亞麻油酸及3 聚物,甚至還有高度聚合的亞麻油酸共聚合物。其中藉由分子蒸 200815042 餾的方法,可以將亞麻油酸2聚物的含量提高到90質量%以上。 又’在得到的亞麻油酸2聚物的不飽和結合中加入氫,可以使其 安定化。將這些亞麻油酸的2聚物加入氫後所得到的,一般稱之 為氳化二聚酸。本發明之二聚亞油酸二乙二醇酯寡聚物,其合成 使用的二聚亞油酸雖然也可以使用上述這些二聚酸以及氫化二聚 酸中的任何一種,但是若由氧化安定性的觀點來看,則以使用氫 化二聚酸較為適當。氳化二聚酸可使用市售品,例如UNIQEMA公 m 零司所生產的 PRIP〇L1〇〇6、PRIP〇L1〇〇9、PRIPOL1025 等。 <二乙二醇> 二乙二醇係一種以〇(CH2CH2〇H) 2之化學式所表示的化合物, 並作為有機合成原料在市場上加以販賣。 將二聚亞油酸與二乙二醇進行酯化反應後聚合,利用其共聚 合作用可崎到二聚亞崎二乙二_旨絲物。自旨化方法沒有特 別規定例如無觸媒或是使用對曱苯石黃酸、硫酸、鹽酸、甲基石黃 酉夂等作為觸媒,無溶媒或是使用甲苯、正己烧㈤職)、庚烷 (h印tane)等作為⑸媒,在5Q〜編。c的溫度下進行反應即可。 構成一來亞油酸與二乙二醇之二聚亞油酸與二乙二醇的比 例以〇· 5莫耳· L 〇莫耳〜〇· 8莫耳:」· 〇莫耳為適當。當二聚 亞/由酉夂 >乙—醇為〇· 5莫耳:I 0莫耳時,會形絲聚物,其是 以一乙一醇於—聚亞油酸的兩端結合後的物質作為中心分布。當 -水亞抓·—乙二醇為〇 8莫耳:L 〇莫耳時,將會形成寡聚物, 200815042 其是以4個二聚亞油酸及5個二乙二醇經酯結合後的物質作為中 心分布。 夕由於不管哪一種方式,其t二乙二醇都會比二聚亞油酸來得 多’因此幾乎不會有剩下的羧基,殘留在寡聚物末端的官能基幾 乎都是氫氧基。當二聚亞油酸與二乙二醇的莫耳比接近〗時,聚 口度會大,而油劑的黏性也會跟著增強,因此並不理想。又, 如果二聚亞油酸的莫耳濃纽二乙二醇多的話,所殘細官能基 將會變成羧基,以安全性的觀點來看不甚理想。 特別是構成的二聚亞油酸及二乙二醇的比例為,二聚亞油 乙一醇〇· 5莫耳.j. 〇莫耳,在25。匸中的黏度為&剛〜 4’ 50〇mPa · s之二聚亞油酸二乙二醇醋寡聚物,可發現其藥物的皮 膚滲透性小,且關激__、财水份蒸散抑卿用,因此 可確定其防止肌膚粗經的效果高。而對於該作用,即使在和類似 的承亞版一乙一醇酯寡聚物相互比較下,也確實有顯著的差 異0 再者,專利文獻6中,雖有針對配合各種二聚亞油酸二乙二 醇醋寡聚物的化妝料予以檢討,但卻沒有討論到刺激緩和作用。 在專利文獻6中,雖揭不有二聚亞油酸二乙二醇醋寡聚物(二聚 酸:^乙二醇=1 : 〇·5) /混合乙醇(二十二鱗:異十八醇: 植物醇9 . 1 · 1)酷,但關於本發明之配合比例,亦即二聚亞油 酸.二乙二醇=〇· 5莫耳:I 0莫耳〜〇. 8莫耳:1. 〇莫耳之二聚 200815042 亞油酸二乙二_旨寡聚物,卻沒有任何揭示,轉極性相異,兩 者的物性、使用性也全然不同。 本發明之錄料+配合的二聚亞油酸二乙二醇轉聚物,其 配合量雖沒有-定的關,但相對於化妝料總量,歧卜邪質(7) The cosmetic according to any one of (2) to (6) which contains 5 to 2% by mass of a poly-linoleic acid diethylene glycol ester oligomer. (1) - a cosmetic agent containing diethylene linoleate diethylene glycol oligomer, which comprises a ratio of dimerized linoleic acid to diethylene glycol, dimerized, / / By Ethylene Glycol = Q · 5 Mo · U Mo ~ G_ 8 Mo · 1 · G Mo. ^ - - According to the present invention, the following effects can be achieved.乂 and 3 have the oil agent. 1. It can provide a cosmetic which is excellent in stimulating the emollient effect. 7 200815042 2. Since the cosmetic absorbing effect of the present invention is superior, it is possible to suppress the isolation and wrap caused by the skin of the agonist (4) by using the cosmetic of the present invention, and to improve the skin by inhibiting the isolation and destruction. It is rough and protects the skin, so it can provide a cosmetic that has excellent skin roughness and excellent health effects. 3. By using the cosmetic of the present invention, skin aging can be maintained by an excellent moisturizing effect against the aging phenomenon caused by dryness accompanying skin irritation, thereby preventing aging. 4. Since the dimer linoleic acid diethylene glycol oligomer used in the cosmetic of the present invention is not sticky, sticky, and glare-sensitive, it is suitable for use in lotions, creams, and the like. Use a cosmetic. [Embodiment] Hereinafter, the present invention will be described in detail. The dimerized linoleic acid diethylene glycol ester oligomer of the present invention is obtained by esterifying dimeric linoleic acid with diethylene glycol. <Dimerized linoleic acid> Dimerized linoleic acid is a dibasic acid generally called a dimer acid, and two molecules of linoleic acid [(9Z, 12Z)-octadec-9 a 2-mer of linoleic acid after polymerization of an unsaturated fatty acid such as 12-dienoic acid. Among the products of the linoleic acid polymerization, in addition to the 2-mer of linoleic acid, unreacted linoleic acid and a trimer are contained, and even a highly polymerized linoleic acid copolymer is contained. Among them, the content of the linoleic acid dimer can be increased to 90% by mass or more by the method of molecular vaporization 200815042. Further, hydrogen can be added to the unsaturated combination of the obtained linoleic acid 2 polymer to stabilize it. The addition of these linoleic acid 2 polymers to hydrogen is generally referred to as deuterated dimer acid. The dimerized linoleic acid diethylene glycol ester oligomer of the present invention, the dimerized linoleic acid used for the synthesis thereof, although any of the above dimer acids and hydrogenated dimer acids may be used, but if it is stabilized by oxidation From a sexual point of view, it is more appropriate to use a hydrogenated dimer acid. For the deuterated dimer acid, a commercially available product such as PRIP〇L1〇〇6, PRIP〇L1〇〇9, PRIPOL1025, etc. produced by UNIQEMA Corporation can be used. <Diethylene glycol> Diethylene glycol is a compound represented by the chemical formula of hydrazine (CH2CH2〇H) 2 and is marketed as a raw material for organic synthesis. The dimerized linoleic acid is polymerized with diethylene glycol to carry out an esterification reaction, and the copolymerization is carried out by the copolymerization of the dimeric yakisaki. There is no specific regulation for the method of self-determination, for example, no catalyst or use of p-benzoic acid, sulfuric acid, hydrochloric acid, methyl scutellaria, etc. as a catalyst, no solvent or use of toluene, hexapril (five), heptane ( H intane), etc. as (5) media, edited in 5Q~. The reaction can be carried out at a temperature of c. The ratio of dimerized linoleic acid to diethylene glycol of linoleic acid and diethylene glycol is 〇····················································· When dimerization / 酉夂 酉夂 乙 乙 乙 莫 莫 莫 : : : : : I I I I I I I I I I I I I I I I I I I 丝 丝 丝 丝 丝 丝 丝 丝 丝 丝 丝 丝 丝The substance is distributed as a center. When -water sub-grain--ethylene glycol is 〇8 mol: L 〇 Mo ear, an oligomer will be formed, 200815042 which is an ester combination of 4 dimerized linoleic acid and 5 diethylene glycol The latter matter is distributed as a center. In either case, t diethylene glycol is more abundant than dimerized linoleic acid. Therefore, there is almost no remaining carboxyl group, and the functional groups remaining at the end of the oligomer are almost all hydroxyl groups. When the molar ratio of dimerized linoleic acid to diethylene glycol is close to that, the degree of aggregation will be large, and the viscosity of the oil agent will increase, so it is not ideal. Further, if the dimerized linoleic acid has a large amount of molybdenum diethylene glycol, the residual functional group will become a carboxyl group, which is not preferable from the viewpoint of safety. In particular, the ratio of the dimerized linoleic acid and the diethylene glycol is composed of dimerized linoleic acid ethyl ketone · 5 mol. j. 〇 Moel, at 25. The viscosity in sputum is & just ~ 4' 50 〇 mPa · s dimerized linoleic acid diethylene glycol vinegar oligomer, it can be found that the drug has small skin permeability, and it is __, wealth It is used for evapotranspiration, so it can be determined that it has a high effect of preventing skin thickening. For this effect, there is a significant difference even when compared with a similar type of acetylene ester oligomer. However, in Patent Document 6, although it is suitable for blending various dimerized linoleic acid The cosmetic of ethylene glycol vinegar oligomers was reviewed, but no stimulating effect was discussed. In Patent Document 6, although dimerized linoleic acid diethylene glycol vinegar oligomer (dimer acid: ^ethylene glycol = 1: 〇·5) / mixed ethanol (twenty-two scale: different ten Octaol: Plant alcohol 9. 1 · 1) Cool, but the proportion of the present invention, that is, dimerized linoleic acid. Diethylene glycol = 〇 · 5 moles: I 0 Moer ~ 〇. 8 Molar :1. 〇莫耳二聚200815042 Linoleic acid diethyl -2- oligopolymer, but there is no disclosure, the polarity is different, the physical properties and usability of the two are completely different. The recording material + the dimerized linoleic acid diethylene glycol telomer of the invention has no fixed amount, but is different from the total amount of the cosmetic material.

量%較為適宜。化妝料若為保濕化妝料時,二聚亞油酸二乙二醇 醋寡聚物的配合量以(U〜4〇 f量%為適宜,而又以5〜2〇質量 %更為適當。若配合量為4〇質量%社的話,會由於黏腻感過於 強烈而不適合作為化妝料;若超過2()質量%以上時,_感就會 變強;然而若配合量在5質量%以下,刺激緩和作用會減弱,在 〇· 1質量%以下時,便幾乎沒有刺激緩和作用了。 本务明的化妝料(包含準藥品(quasi_drug)),可列舉出化 妝水、乳液、乳霜、護手霜、身體乳液、美容液、防曬乳劑、粉 底液、口紅等。由於本發明的化妝料具有顯著的刺激緩和效果及 肌膚粗糙防止效果,因此非常適合用在保濕化妝料 。作為保濕化 妝料者,可以列舉出化妝水、乳液、乳霜、護手霜、身體乳液、 美谷液等。 本發明之化妝料,配合其用途、使用目的、用劑型態等,可 、吏>、5有如植物油的油脂類、南級脂肪酸、南級乙醇、陰離子 界面活性劑、陽離子界面活性劑、兩性界面活性劑、非離子界面 活性劑、防腐劑、糖類、金屬離子封鎖劑、粉體成份、紫外線吸 收劑、紫外線隔離劑、如玻尿酸的保濕劑、香料、pH調整劑等。 11 200815042 =外也可使其含有維生素類、皮膚活侧、血崎雜進劑、益 菌㈣4、雜氧》肖除劑、抗發炎劑、美白劑、殺g劑等其他藥 效成分、生理活性成分。 關於油脂類’可列舉出樁油、胤草油、夏威夷核果(澳洲 堅果)U、橄欖油、油菜籽油、玉米油、芝麻油、荷荷巴油、 胚芽油、小麥胚芽油、三辛酸甘油等液體油脂、可可子油、挪子 油、硬化椰子油、棕櫚油、棕櫚核油、木壞核油、硬化油、硬化 莲麻油等固體油脂、蜜躐、堪地里躐、綿犧、糠壞、羊毛脂、醋 酸羊毛脂、液狀羊毛脂、甘蔗财麵、流動石蟻、麟、級油、 微晶壤等。 關於高級脂肪酸,可列舉出月桂酸(lauHc acid)、肉莖蔻 酸(myristic acid)、棕櫚酸、硬脂酸、油酸、亞麻油酸、亞麻 油酸(1 inolenic acid)、二十二碳六烯酸(d〇c〇sahexaen〇ic acid) (DHA)、一十碳五烯酸(eic〇saperrtaen〇ic add) (epa)等。 關於高級乙醇,可列舉出月桂醇、硬脂醇、鯨蠟醇、硬脂酸 十六醇(cetostearyl alcohol )等直鏈醇類、單硬脂甘油醚 (monostearyl glycerin ether)、羊毛脂醇、膽固醇 (cholesterol)' 植物留醇(phytosterol)、辛基十二醇(octyl dodecanol)等分支鏈醇類等。 關於陰離子界面活性劑,可列舉出月桂酸鈉等脂肪酸鹽、月 桂基硫酸鈉(sodium lauryl sulfate)等高級烷基硫酸酯鹽、poe 12 200815042 月桂基硫酸三乙醇胺(triethanolamine)等烧醚硫酸酯鹽、N — 酰基肌氨酸(acylsarcosinate)、磺基琥珀酸鹽、N —醯基胺基 酸(acylamino acid)鹽等。 關於陽離子界面活性劑,可列舉出氯化硬脂三曱基銨等烷基 三甲基銨(alkyltrimethylammonium)鹽、苯扎氯銨(benzalkonium chloride)、下索氯|安(benzethonium chloride)等。 關於兩性界面活性劑,可列舉出烷基甜菜鹼(alkyl ⑩betaine)、酰胺基甜菜鹼(amidobetaine)等甜菜鹼系界面活性 劑等。 關於非離子界面活性劑,可列舉出脫水山梨醇單油酸酯 (sorbitanmonooleate)等脫水山梨醇脂肪酸酯類、硬化蓖麻油 衍生物。 關於防腐劑,可列舉出對經基苯甲酸甲醋(methyl paraben>、 對羥基苯曱酸乙酯(ethyl paraben)等。 • 關於金屬離子封鎖劑,可列舉出乙二胺四乙酸二鈉(disodium ethylenediaminetetraacetate)、_ 酸、腿酸納鹽等顧 酸鹽。 =抑制械感、並增加色彩,_粉末成分,可列舉出滑 石、高嶺土、雲母、娃、沸石、聚乙烯粉末、聚苯乙稀粉末、纖 維素粉末、無機白色顏料、無機紅色系顏料、二氧化鈦包覆雲母、 -氧化鈦包仙石、著色二氧化鈦包覆雲母等珠光顏料、紅色 13 200815042 號、紅色202號等煤焦色素(tar dye)。 關於紫外線吸_ ’可解㈣氨絲f acid)、水揚酸苯酯(phenyl saiicylate)、對甲氧基桂皮酸異丙 酯(isopropyl p-meth〇xyCinnamate>對甲氧基桂皮酸辛醋(〇ctyl p-methoxycinnamate)、2, 4-二羥基二苯@同 C dihydroxybenzophenone)等。 關於紫外線隔離劑,可列舉出氧化鈦、滑石、胭脂蟲紅素 _ (carmine)、膨潤土、高嶺土、氧化鋅等。 關於保濕劑,可列舉出木糖醇、麥芽糖醇、麥芽糖、山梨糖 醇、葡萄糖、果糖、嚴糖、乳糖、軟骨素硫酸納(s〇dium ch〇ndr〇丨tin sulfate)、玻尿酸鈉(sodium hyaluronate)、乳酸納(sodium lactate)、吼咯烧酮羧酸(pyrr〇iid〇ne carboxylic acid)、環 狀糊精(cyclodextrin)等。 關於藥效成分,可列舉出維生素A油、視黃醇等維生素a類、 核黃素等維生素B 2類、吡哆辛鹽酸鹽等b 6類、泛酸鈣等泛酸類、 維生素D2、膽舞化醇(ch〇lecaicifer〇i)等維生素d類、α_ 生月醇、醋酸生育醇酯(tocopherol acetate)、尼古丁酸DL— α 一生育醇(DL-α-tocopherol nicothinate)等維生素Ε類等維 生素類。 其他還可列舉出蜂王漿、山毛櫸萃取物等皮膚活化劑、辣椒 素、量育素(zingerone)、斑螯素(cantharides tincture)、魚 < i > 14 200815042 石脂、咖啡因、單等酸、7"—谷維素(7-〇ryZan〇i )等血液循環 促進劑、甘草酸(glycyrrhizic acid)衍生物、甘草次酸 (glycyrrhetinicacid)衍生物、甘菊藍(azulene)等消炎劑、 ‘ 精氨酸(arginine)、絲氨酸(serine)、亮氨酸(leucine)、色 - 氨酸(廿Tptophan)等氨基酸類、益菌控制劑之麥芽糖蔗糖縮合 物(condensation)、氯化溶菌酶(lysozyme chloride)等。 此外,還可以配合如洋甘菊萃取物、荷蘭芹萃取物、紅酒酵 • 母萃取物、葡萄柚萃取物、金銀花萃取物、米萃取物、葡萄萃取 物、啤酒花萃取物、米糠萃取物、枇杷萃取物、黃檗萃取物、薏 仁萃取物、當藥(Swertia japonica)萃取物、黃香草木樨 (Melilotus officinalis)萃取物、樺木(burch)萃取物、芍 藥萃取物、石鹼草(Saponaria officinalis)萃取物、絲瓜萃取 物、紅椒萃取物、檸檬萃取物、龍膽草萃取物、紫蘇萃取物、蘆 薈萃取物、迷迭香萃取物、鼠尾草萃取物、百里香萃取物、茶葉 馨萃取物、海藻萃取物、黃瓜萃取物、丁香萃取物、七葉樹(horse chestnut)萃取物、金縷梅(hamamelis)萃取物、桑樹萃取物等 各種萃取物。 (實施例1) 二聚亞油酸二乙二醇酯寡聚物(二聚亞油酸··二乙二醇=0· 5 莫耳:1. 〇莫耳)以實施例1表示其製造方法。 於具備攪拌機、溫度計、氣體導入管之1L的反應器中,饋入 15 200815042 二聚亞油酸(UNIQEMA公司製prip〇u〇25) 349g (〇· 6莫耳)及二 乙一醇127g(1.2莫耳)’在氮氣環境中加熱至21〇〜22〇ι,一邊 將生成的水分蒸發-邊進行12小時_旨化反應,最後得到淡黃色 而黏度油狀物的二聚亞崎二乙二_旨絲物(二聚亞油酸:二 乙二醇= 〇·5 : 1·〇)(以下表示如「deg_M5」)4跑。 所得到的3種油劑的物性值如以下表丨所示。 [表1] 種類 黏度(25°C) (mPa · s) 分子量 氺1) 酸價 曲折率 種類1 3320 1,470 1.0 1.4733 種類2 3328 1,500 1.0 1.4733 種類3 3175 1,500 1.0 1.4733 *1)以GPC法所測量之數平均分子量 (實施例2) 將二聚亞油酸二乙二醇酯寡聚物(二聚亞油酸:二乙二醇= 〇·8莫耳:1·〇莫耳)以實施例2,表示其製造方法。 於具備攪拌機、溫度計、氣體導入管之1L的反應器中,裝入 二聚亞油酸(UNIQEMA公司製PRIPOL1025) 372g (0.64莫耳)以 及二乙二醇84· 8g (〇· 8莫耳),在通以氮氣流下加熱至210〜220 C ’ ^~邊將生成的水分蒸發一邊進行14小時的S旨化反應’隶後付 到淡買色面黏度油狀物的二聚亞油酸二乙二醇g旨寡聚物( >一聚亞 16 200815042 夂乙一醇〇·8· ΐ· 〇)(以下也有以「娜—應」表示)375g。 所得到油劑的物性值如以下表2所示。 [表2] 、不The amount % is more suitable. When the cosmetic is a moisturizing cosmetic, the amount of the dimerized linoleic acid diethylene glycol vinegar oligomer is suitably (U~4〇f%, and more preferably 5 to 2% by mass). If the blending amount is 4% by mass, it will not be suitable as a cosmetic because the stickiness is too strong; if it exceeds 2 ()% by mass or more, the sensation will become stronger; however, if the blending amount is 5% by mass or less The stimulating effect will be weakened, and when it is less than 1% by mass, there is almost no stimulating effect. The cosmetic materials (including quasi-drugs) include lotions, lotions, creams, Hand cream, body lotion, beauty lotion, sunscreen lotion, liquid foundation, lipstick, etc. Since the cosmetic of the present invention has a remarkable stimulating effect and a skin roughness preventing effect, it is very suitable for use as a moisturizing cosmetic. The lotion, the lotion, the cream, the hand cream, the body lotion, the melamine liquid, etc. may be mentioned. The cosmetic of the present invention may be used in accordance with the purpose, purpose of use, dosage form, etc. 5 oil like vegetable oil Lipid, southern fatty acid, southern ethanol, anionic surfactant, cationic surfactant, amphoteric surfactant, nonionic surfactant, preservative, sugar, metal ion blocker, powder component, UV absorber, UV-blocking agents, such as hyaluronic acid moisturizers, perfumes, pH adjusters, etc. 11 200815042 = It can also contain vitamins, skin side, blood-staining agent, beneficial bacteria (4) 4, hypoxia, remover, Other medicinal ingredients and physiologically active ingredients such as anti-inflammatory agents, whitening agents, and gluing agents. Examples of oils and fats include pile oil, valerian oil, Hawaiian stone fruit (Macadamia nut) U, olive oil, rapeseed oil, and corn. Oil, sesame oil, jojoba oil, germ oil, wheat germ oil, tricapry glycerol and other liquid fats, cocoa butter, raisin oil, hardened coconut oil, palm oil, palm kernel oil, wood bad nuclear oil, hardened oil, Solid oil such as hardened lotus oil, candied fruit, candied fruit, cotton sacrifice, smashed, lanolin, lanolin acetate, liquid lanolin, sugar cane, mobile stone ants, lin, grade oil, micro For higher fatty acids, lauHc acid, myristic acid, palmitic acid, stearic acid, oleic acid, linoleic acid, linoleic acid (1 inolenic acid), and Docosahexaenoic acid (DHA), eic〇saperrtaen〇ic add (epa), etc. Regarding higher alcohol, lauryl alcohol, hard Linear alcohols such as aliphatic alcohol, cetyl alcohol, cetostearyl alcohol, monostearyl glycerin ether, lanolin alcohol, cholesterol (phytosterol), phytosterol, a branched chain alcohol such as octyl dodecanol. Examples of the anionic surfactant include fatty acid salts such as sodium laurate and higher alkyl sulfates such as sodium lauryl sulfate, and burnt ether sulfates such as poe 12 200815042 triethanolamine. , N - acylsarcosine, sulfosuccinate, N-decylamino acid salt, and the like. The cationic surfactant may, for example, be an alkyltrimethylammonium salt such as stearyl triammonium chloride, benzalkonium chloride or benzethonium chloride. The amphoteric surfactant may, for example, be a betaine-based surfactant such as an alkyl 10betaine or an amidobetaine. Examples of the nonionic surfactant include sorbitan fatty acid esters such as sorbitan monooleate and hardened castor oil derivatives. Examples of the preservative include methyl paraben>, ethyl paraben, etc. • Regarding the metal ion blocking agent, disodium edetate (sodium diamine tetraacetate) Disodium ethylenediaminetetraacetate), _ acid, sodium salt and other salts. = inhibit the mechanical sense, and increase the color, _ powder composition, can be listed as talc, kaolin, mica, baby, zeolite, polyethylene powder, polystyrene Powder, cellulose powder, inorganic white pigment, inorganic red pigment, titanium dioxide coated mica, titanium oxide coated stone, pigmented titanium dioxide coated mica and other pearlescent pigments, red 13 200815042, red 202 and other coal char pigments (tar dye About UV absorption _ 'solvable (four) ammonia f acid), phenyl saiicylate, isopropyl p-meth〇xyCinnamate> p-methoxy cinnamic acid vinegar (〇ctyl p-methoxycinnamate), 2, 4-dihydroxydiphenyl@同C dihydroxybenzophenone), and the like. Examples of the ultraviolet ray release agent include titanium oxide, talc, carmine, bentonite, kaolin, and zinc oxide. Examples of the humectant include xylitol, maltitol, maltose, sorbitol, glucose, fructose, sucrose, lactose, s〇dium ch〇ndr〇丨tin sulfate, and sodium hyaluronate (sodium). Hyaluronate), sodium lactate, pyrr〇iid〇ne carboxylic acid, cyclodextrin, and the like. Examples of the medicinal ingredient include vitamin A such as vitamin A oil and retinol, vitamin B 2 such as riboflavin, b 6 such as pyridoxine hydrochloride, pantothenic acid such as calcium pantothenate, and vitamin D2. Vitamin D, such as ch〇lecaicifer〇i, tocopherol acetate, DL-α-tocopherol nicothinate, etc. Vitamins. Other examples include skin activators such as royal jelly and beech extract, capsaicin, zingerone, cantharides tincture, and fish<i> 14 200815042 stone fat, caffeine, monoacid , 7"-[7-〇ryZan〇i) and other blood circulation promoters, glycyrrhizic acid derivatives, glycyrrhetinic acid derivatives, azulene and other anti-inflammatory agents, 'sperm ammonia Amino acids such as arginine, serine, leucine, and 廿Tptophan, maltose sucrose condensate of beneficial bacteria control agent, lysozyme chloride Wait. In addition, it can also be combined with such as chamomile extract, parsley extract, red wine yeast extract, grapefruit extract, honeysuckle extract, rice extract, grape extract, hop extract, rice bran extract, alfalfa extract , Astragalus extract, Coix seed extract, Swertia japonica extract, Melilotus officinalis extract, bich extract, peony extract, Saponaria officinalis extract, Loofah extract, red pepper extract, lemon extract, gentian extract, perilla extract, aloe extract, rosemary extract, sage extract, thyme extract, tea scent extract, algae extract Various extracts such as extracts, cucumber extract, clove extract, horse chestnut extract, hamamelis extract, mulberry extract, and the like. (Example 1) Diethylene linoleic acid diethylene glycol ester oligomer (dimerized linoleic acid · diethylene glycol = 0 · 5 mole: 1. 〇 Mo ear) is shown in Example 1 method. In a reactor equipped with a stirrer, a thermometer, and a gas introduction tube, a feed of 15 200815042 dimerized linoleic acid (prip〇u〇25 manufactured by UNIQEMA Co., Ltd.) 349g (〇·6 mol) and diacetyl alcohol 127g (1.2) Moer) 'heated to 21 〇 to 22 〇 in a nitrogen atmosphere, and evaporates the generated water for 12 hours. The final reaction yields a yellowish, viscous oily dimerization. _The target (dimerized linoleic acid: diethylene glycol = 〇·5: 1·〇) (hereinafter referred to as "deg_M5") 4 runs. The physical property values of the obtained three oil agents are shown in the following table. [Table 1] Type of viscosity (25 ° C) (mPa · s) Molecular weight 氺 1) Acid value tortuosity type 1 3320 1,470 1.0 1.4733 Type 2 3328 1,500 1.0 1.4733 Type 3 3175 1,500 1.0 1.4733 *1) Measured by GPC method Number average molecular weight (Example 2) Diethylene linoleate diethylene glycol oligomer (dimer linoleic acid: diethylene glycol = 〇·8 mol: 1·〇莫耳) as an example 2, indicating its manufacturing method. In a reactor equipped with a stirrer, a thermometer, and a gas introduction tube, a dimerized linoleic acid (PRIPOL1025 manufactured by UNIQEMA Co., Ltd.) 372 g (0.64 mol) and diethylene glycol 84·8 g (〇·8 mol) were charged. , after heating to 210~220 C ' ^~ under a nitrogen stream, the generated water is evaporated while performing a 14-hour S-reaction reaction, and then the dimerized linoleic acid is added to the light-paste oil. Ethylene glycol g oligo (> 聚聚亚16 200815042 夂 一 〇 8 8 · 〇 ( ( ( () (hereinafter also referred to as "Na - Ying") 375g. The physical property values of the obtained oil agents are shown in Table 2 below. [Table 2], no

黏度(25°C) (mPa · s) 40000 種類1Viscosity (25 ° C) (mPa · s) 40000 Category 1

酸價 曲折率 ";------ 1.7 —1.4753 i藥物皮膚滲逢眚^1 將實施例1之油劑與市售之二聚酸醋、二聚二醇_,針對其 藥物皮膚滲透性做評價。 1.試料 如表3所示,於實施例1所得到的油劑(DEG—Μ5)及市售 的一聚酸酯、二聚二醇酯中,使用溶解有1%異丁苯丙酸(Sigma) 的試料,實施藥物皮膚滲透實驗。 2.貫驗方法 將冷凌保存在-8(TC的Yucatan Micropig背部皮膚(5個月 大、雌性,日本CHARLES RIVER (股)),放在室溫下解凍3〇分鐘, 除去附在皮膚上的多餘脂肪後,切成大約2cm的正方形用來實驗。 將皮膚以有效面積0.95cm2夾在細胞之間,塗布上試料 0.2ml。經過48小時後藉由擦拭去除皮膚表面的試料,在甲醇/ 0· 1%填酸水溶液混合液(70 : 30)中,利用録子及均質機 17 < η > 200815042 (homogemzer)將皮膚弄碎後抽出異丁苯丙酸(或是異丁苯乙酸 (ibuprofen)),依照HPLC來測量皮膚中的異丁苯丙酸量。測量 結果如表3所示。 2·1 HPLC測量條件 檢出器:紫外線吸光光度計LC—10AD ((股)島津製作所製) 測量波長:220nm 層析管:TSK-GEL ODS-80Ts 4.6mmxl50mm (東所(股)) 移動相:曱醇:0· 1%鱗酸水溶液=75 : 25 流速:lml/分 2.2資料處理 使用CLASS—VP (島津製作所(股)製),依照異丁苯丙酸的 波峰面積做成不同的檢量線,計算後求得其濃度。 3.結果 測量結果如表3所示。 異丁苯丙酸一般是用來作為經皮吸收性的指標。若皮膚對異 丁苯丙酸的吸收量較少,則代表其抑制刺激物質的吸收的效果佳。 將異丁苯丙酸溶解於實施例1之油劑(DEG—DA5)時,經過 48小時後皮膚中異丁苯丙酸量為21 ,對於此情況,溶解於市 售的二聚酸i曰、'一一醇S曰日寸’異丁本丙酸量為37//g/^^70/zg。 即使是在二聚酸酯、二聚二醇酯中,實施例1的油劑(DEG—DA5) 對於抑制異丁笨丙酸滲透入皮膚的效果極佳、刺激物質的吸收抑 200815042 制效果也很優異。市售油劑中,雖然LUSPLAN DD—DHR:日本精化(股)Acid value tortuosity rate ";------ 1.7 -1.4753 i drug skin permeation ^1 The oil of Example 1 and commercially available dimer acid vinegar, dimer diol _, for its drug skin Permeability is evaluated. 1. Samples As shown in Table 3, in the oil agent (DEG-Μ5) obtained in Example 1 and a commercially available mono- or di-glycol ester, 1% ibuprofen was dissolved ( Sigma) samples were tested for drug skin penetration. 2. The method of continuous preservation is to store the cold linger on the back skin of -8 (TC of Yucatan Micropig (5 months old, female, CHARLES RIVER, Japan), and thaw at room temperature for 3 minutes, remove the skin. After excess fat, cut into squares of about 2 cm for experiment. The skin was sandwiched between cells at an effective area of 0.95 cm 2 and coated with 0.2 ml of the sample. After 48 hours, the sample on the skin surface was removed by wiping, in methanol / 0·1% aqueous acid solution mixture (70: 30), using the recording and homogenizer 17 < η > 200815042 (homogemzer) to break the skin and then extract ibuprofen (or isobutyl phenylacetate) (ibuprofen)), the amount of ibuprofen in the skin was measured by HPLC. The measurement results are shown in Table 3. 2.1 HPLC measurement condition detector: UV spectrophotometer LC-10AD ((share) Shimadzu Manufacturing Co., Ltd.) Measurement wavelength: 220nm Chromatography: TSK-GEL ODS-80Ts 4.6mmxl50mm (East (share)) Mobile phase: decyl alcohol: 0·1% squaric acid aqueous solution = 75 : 25 Flow rate: lml / min 2.2 data processing Use CLASS-VP (Shimadzu Corporation (stock) system), in accordance with ibuprofen The peak area is made into different calibration lines, and the concentration is calculated after calculation. 3. The results of the measurement are shown in Table 3. Ibuprofen is generally used as an indicator of transdermal absorption. The absorption of styrene-butanoic acid is small, which means that the effect of inhibiting the absorption of the stimulating substance is good. When ibuprofen is dissolved in the oil agent of Example 1 (DEG-DA5), the skin is different after 48 hours. The amount of styrene-butanoic acid was 21, and in this case, the amount of the commercially available dimer acid i曰, 'mono-alcohol S 曰 寸', and the amount of the isobutyric acid was 37//g/^^70/zg. Even in the dimer acid ester or dimer diol ester, the oil agent (DEG-DA5) of Example 1 has an excellent effect of inhibiting the penetration of the isobutyric acid into the skin, and the absorption of the stimulating substance is also inhibited. Very good. In the market oil agent, although LUSPLAN DD-DHR: Japan Elaboration (shares)

製二聚亞油醇氫化松脂共聚物(異丁苯丙酸量37#g)、LUSpLAN DD-DA7:日本精化(股)製二聚亞油酸二聚亞油醇(異丁苯丙酸量 42//g)之異丁苯丙酸的吸收量也屬於較低的,但兩種油劑的黏性 都偏咼,黏腻感強烈,且具眩光感,所以難以用於保濕化妝料。 [表3] 表3 溶解1%異丁苯丙酸後的油劑 經過48小時後皮膚中的異丁苯丙酸量(# g) 實施例1的油劑(DEG-DA5) 21 LUSPLAN DD-DHR 37 LUSPLAN DD-DA7 42 LUSPLAN PI-DA 53Dimerized linoleyl hydrogenated rosin copolymer (Ibuprofen amount 37#g), LUSpLAN DD-DA7: Diuretic linoleic acid dimerized linoleic alcohol (Ibuprofen) manufactured by Nippon Seika Co., Ltd. The amount of ibuprofen absorbed by 42//g) is also low, but the viscosity of both oils is partial, sticky and glare, so it is difficult to use for moisturizing cosmetics. . [Table 3] Table 3 The amount of ibuprofen in the skin after 48 hours of dissolving 1% ibuprofen (#g) The oil of Example 1 (DEG-DA5) 21 LUSPLAN DD- DHR 37 LUSPLAN DD-DA7 42 LUSPLAN PI-DA 53

LUSPLAN DD-IS 70 LUSPLAN DD-DHR:日本精化㈤製三聚亞油醇氫化松脂共聚物 LUSPLAOD-DA7 :日本精化(股)製二聚亞油酸二聚亞油醇 LUSPLAN PI-DA:曰本精化(股)製二聚亞油酸(合成醋/植物 LUSPLAN DD一IS ··日本精化(月二硬脂酸二聚亞 ^利用膠原凝膠法進行和性實驗> 將實施例1調製而成的油劑⑽—廳)、實施例2調製而成 的油劑(DEG-DA8)與市售的油劑,對刺激緩和作用進行比較。 1·受驗物質 將表4所示之關依絲,或將據報姑㈣動物或人類皮 膚具有刺激性的月桂酸’則5質量%、〇8 旦 0 U 貝!% 19 200815042 添加入油劑中,作為受驗物質。 2.實驗方法 2· 1膠原凝膠的製作 將Type I—AC膠原蛋白(高研)水溶液與正常人類纖維芽細 胞(CAMBLEX製)的媒介中懸濁液,以及適量的重建液,以攪拌器 混合調製,使Type i—AC膠原蛋白(高研)的最終濃度為〇. i質 量%、正常人類纖維芽細胞(CAMBLEX製)的最終濃度為4. 〇xLUSPLAN DD-IS 70 LUSPLAN DD-DHR: Japan's refined (5) tripoly linoleyl hydrogenated rosin copolymer LUSPLAOD-DA7: Japan's refined (share) dimerized linoleic acid dimerized linoleic alcohol LUSPLAN PI-DA:曰本精化(股)制制聚聚酸酸(synthetic vinegar/plant LUSPLAN DD一IS ··Japan Refined (Monthium stearate dimerization] using collagen gel method for symmetry experiment > will be implemented The oil agent (10) prepared in Example 1 and the oil agent (DEG-DA8) prepared in Example 2 were compared with commercially available oil agents to compare the effects of stimulation and relaxation. It is indicated that the silk is scented, or the lauric acid which is reported to be irritating to the animal or human skin, is 5 mass%, 〇8 denier 0 U shell!% 19 200815042 is added to the oil as a test substance. Experimental Method 2·1 Preparation of Collagen Gel A suspension of Type I-AC collagen (Gaoyan) aqueous solution and normal human fibroblasts (manufactured by CAMBEX), and an appropriate amount of reconstituted solution were mixed with a stirrer. Modulation, the final concentration of Type i-AC collagen (Gaoyan) is 〇. i mass%, normal human fibroblasts CAMBLEX Ltd.) to a final concentration of 4 〇x

10 cells/mL,於 6 孔培養盤内槽(6 weu cuiture insert,FALC〇N 製)滴下lmL。培養媒介則使用DMEM+1〇%FBS。將膠原蛋白培養 約16 (12小時〜24小時)個小時。 2.2對受驗物質的膠原凝膠的適用性 在2· 1所製作的膠原凝膠上,分別添加〇· 5質量%、〇 8質量 %、1.2質量%的月桂酸,及ig的無添加受驗物質,暴露%個小 牯。經過24小時的暴露後去除受驗物質,利用MTTassay測量、 計算出細胞存活率,調查細胞生存率的月桂酸濃度依存性。 3·結果 結果如表4所示。 二聚亞油酸二乙二醇酯寡聚物(二聚亞油酸··二乙二醇= 〇.5: 1.0)即使在添加了 1.2質量%的月桂酸後,細胞存活率仍 約為80% ’由此可知其刺激緩和效果極佳。比起沒有添加月桂酸 者’添加0. 5%月桂酸者的細胞存活率在數據上雖然提高(實施例 20 200815042 1 所調製的油劑(DEG—DA5)為 95%—104%,LUSPLAN DD-IS 則 為72%—78%) ’但這是由於資料雜亂所造成的結果。 [表4] 細胞存活率實驗結果(%) 表4 油劑 月桂酸添加濃度(%) 0 0.5 0.8 1.2 實施例1所調製之油劑(DEG-DA5 ) 95 104 91 77 實施例2所調製之油劑(DEG-DA8 ) 107 80 42 16 LUSPLAN DD-IS 72 78 23 6 LUSPLAN PI-DA 62 51 49 18 大豆油 93 49 4 4 澳洲堅果籽油 84 16 3 1 3 麻油 74 74 「37 9 葵花油 87 71 14 2 流動石纖 86 3 4 -—-— 3 橄欖鯊烯 -----—^ 96 3 3 2 棕櫚酸異丙烷基 68 29 ---— 2 — 2 棕櫚酸辛酯 73 56 1 ----~:— 2 辛酸絲堪 38 14 2 2 新戊烷酸合成酯 80 35 '——. 11 —---- 3 LUSPLAN PI-Μ :日本精化(股)製 二硬脂酸二聚亞油醇 二聚亞油酸(合成酯/植物 醇) <利用細胞進行刺激縘>10 cells/mL, 1 mL was dropped in a 6-well culture dish (6 weu cuiture insert, manufactured by FALC® N). The culture medium uses DMEM+1〇%FBS. Collagen is cultured for approximately 16 (12 hours to 24 hours) hours. 2.2 Applicability to the collagen gel of the test substance: 5% mass%, 〇8 mass%, 1.2 mass% of lauric acid were added to the collagen gel prepared in 2.1, and ig was added. Check the substance and expose % of the small defects. After 24 hours of exposure, the test substance was removed, and the cell survival rate was measured by MTTassay, and the lauric acid concentration dependence of the cell survival rate was investigated. 3. Results The results are shown in Table 4. Dimerized linoleic acid diethylene glycol ester oligomer (dimerized linoleic acid · diethylene glycol = 〇. 5: 1.0) Even after the addition of 1.2% by mass of lauric acid, the cell survival rate is still about 80% 'This shows that its stimulating effect is excellent. Compared with the case of no lauric acid added, the cell viability of the person who added 0.5% lauric acid increased although the data was improved (Example 20 200815042 1 The oil agent (DEG-DA5) was 95%-104%, LUSPLAN DD -IS is 72% - 78%) 'But this is the result of data clutter. [Table 4] Cell viability test results (%) Table 4 Oil agent lauric acid added concentration (%) 0 0.5 0.8 1.2 The oil agent prepared in Example 1 (DEG-DA5) 95 104 91 77 The preparation of Example 2 Oil (DEG-DA8 ) 107 80 42 16 LUSPLAN DD-IS 72 78 23 6 LUSPLAN PI-DA 62 51 49 18 Soybean Oil 93 49 4 4 Macadamia Seed Oil 84 16 3 1 3 Sesame Oil 74 74 "37 9 Sunflower Oil 87 71 14 2 Flowing stone fiber 86 3 4 ---- 3 Olive squalene------^ 96 3 3 2 Isopropyl palmitate 68 29 ---— 2 — 2 octyl palmitate 73 56 1 - ---~:— 2 octanoic acid silk 38 14 2 2 neopentanoic acid synthetic ester 80 35 '——. 11 —---- 3 LUSPLAN PI-Μ : Japan's refined (share) system of distearic acid II Polyarylene alcohol dimerized linoleic acid (synthetic ester/phytol) <Using cells for stimulation 縘>

21 200815042 將添加月桂基硫酸鈉的乳霜使用於正常人類纖維芽細胞上, 調查乳霜對於月桂基硫酸鈉的刺激缓和效果。 1·受驗乳霜 使用如表5所示處方之乳霜,即實施例3、比較例1、比較例 2的乳霜,將各乳霜、以及其乳霜中添加10%月桂基硫酸鈉水溶 液使其混合,將乳霜中月桂基硫酸鈉的含量調整為〇· 1%後加以使 用。 _ [表 5] 表5 實施例3 比較例1 比較例2 油 劑 實施例1的油劑(DEG-DA5) 20.0 流動石蠟 20.0 鯊烯 20.0 油 劑 以 外 的 成 分 山蓊醇 3.0 3.0 3.0 甘油 30.0 30.0 30.0 1,3-丁二醇 4.0 4.0 4.0 麥芽糖醇 0.4 0.4 0.4 蝦紅素 0.1 0.1 0.1 羧乙烯基聚合物 0.5 0.5 0.5 三仙膠 0.1 0.1 0.1 單硬脂酸十聚甘油酯 1.0 L0 1.0 精胺酸 0.5 0.5 0· 5 水 殘留 殘留 殘留 22 200815042 2.實驗方法 將受驗乳霜於媒介中混合稀釋。 將正常人類纖維芽細胞播種於96孔平盤,播種面積為3. 5x 1〇3 ’培養5天。 在單層細胞密著的狀態下,為使受驗乳霜的濃度成為0· 156 % 20% ’置換為混合稀釋後的媒介,將細胞暴露於受驗乳霜中。 經過20個小時的暴露後,使用MTT分析法求出細胞存活率。 _ 3.結果 將不含月桂基硫酸鈉的乳霜,於各種濃度下暴露於細胞時的 存活率以圖1表示;將含有〇· 1%濃度月桂基硫酸納的乳霜,於各 種濃度下暴露於細胞時的存活率以圖2表示。 如圖1所不’各例全都是,將不含月桂基硫酸鈉的乳霜,於 各種濃度下暴露於細胞時,隨著媒介中的乳霜濃度從〇· 156%增大 至20%,存活率大致同樣地從8〇%降低至6〇%。 另外’如圖2所示,將含有〇· 濃度月桂基硫酸鈉的乳霜, 於各種濃度下暴露於細胞時,即使將媒介中的乳霜濃度從〇156 %增大至10%,各例全都是,細胞存活率大致同樣地從8〇%降低 至 70%。 然而’當媒介中的乳霜濃度調至2〇%時,實施例3中含有〇· 1 %濃度月桂基硫酸鈉的乳霜,雖然能維持54%的細胞存活率,但 比較例1及2中含有〇· 1%濃度月桂基硫酸鈉的乳霜,其中的細胞 23 200815042 卻幾乎都呈現死亡的狀態(細胞存活率1%)。 因此,實施例3的乳霜對於緩和月桂基硫酸納的刺激,效果 特別優異。21 200815042 A cream containing sodium lauryl sulfate was applied to normal human fibroblasts to investigate the stimulating effect of the cream on sodium lauryl sulfate. 1. The cream to be tested was a cream prescribed in Table 5, that is, the creams of Example 3, Comparative Example 1, and Comparative Example 2, and 10% of sodium lauryl sulfate was added to each cream and its cream. The aqueous solution was mixed, and the content of sodium lauryl sulfate in the cream was adjusted to 〇·1%, and then used. _ [Table 5] Table 5 Example 3 Comparative Example 1 Comparative Example 2 Oil agent Oil agent of Example 1 (DEG-DA5) 20.0 Flowed paraffin 20.0 Squalene 20.0 Ingredients other than oil The behenol 3.0 3.0 3.0 Glycerol 30.0 30.0 30.0 1,3-butanediol 4.0 4.0 4.0 Maltitol 0.4 0.4 0.4 Astaxanthin 0.1 0.1 0.1 Carboxyvinyl polymer 0.5 0.5 0.5 Sanxian gum 0.1 0.1 0.1 Stearic acid monoglyceride 1.0 L0 1.0 Arginine 0.5 0.5 0· 5 Residual residue of water residue 22 200815042 2. Experimental method The tested cream is mixed and diluted in the medium. The normal human fibroblasts were sown in a 96-well plate with a seeding area of 3.5×1〇3 ′ for 5 days. The cells were exposed to the test cream in a state in which the monolayer cells were adhered to each other so that the concentration of the test cream became 0·156% 20%'. After 20 hours of exposure, cell viability was determined using MTT assay. _ 3. The result will be a cream containing sodium lauryl sulfate, the survival rate when exposed to cells at various concentrations is shown in Figure 1; a cream containing 〇·1% concentration of sodium lauryl sulfate at various concentrations The survival rate when exposed to cells is shown in Figure 2. As shown in Figure 1, the creams containing sodium lauryl sulfate are exposed to cells at various concentrations, and the concentration of the cream in the medium increases from 〇·156% to 20%. The survival rate was approximately reduced from 8〇% to 6〇%. In addition, as shown in Fig. 2, when the cream containing sodium sulphate concentration of sodium lauryl sulfate was exposed to cells at various concentrations, even if the concentration of the cream in the medium was increased from 〇156% to 10%, each case All of them, the cell survival rate was roughly reduced from 8〇% to 70%. However, when the cream concentration in the medium was adjusted to 2% by weight, the cream containing 〇·1% sodium lauryl sulfate in Example 3, although maintaining a cell survival rate of 54%, Comparative Examples 1 and 2 The cream containing 〇·1% concentration of sodium lauryl sulfate, in which the cells 23 200815042 almost all showed a state of death (cell survival rate of 1%). Therefore, the cream of Example 3 is particularly excellent in stimulating the stimulation of sodium lauryl sulfate.

針對實施例1的油劑、混合實施例丨的油劑的乳霜(作為實 知例3)、流動石躐、混合流動石躐的乳霜(比較例}),利用貼膚 測試評價月桂基硫酸鈉刺激的緩和效果。 1·前處理受驗品 將實施例1的油劑、流動石蝶以及表5組成之實施例3、比較 例1的乳霜,在用於貼膚測試的受驗品前,先塗布在皮膚上。 2·貼膚測試受驗品 將〇· 5%月桂基硫酸納水溶液與無菌水(sterilized财你) (對知)作為貼膚受驗品。 3·受驗者 、…利用在之前的貼膚測試中,對於月桂基硫酸納〇 ι〜〇厲水 夜壬現擬陽性反應以上,貼附部位沒有出現發癢、秘子等皮 胃症狀健康的2〇〜5〇歲年齡層的人士 ^名(男3名、女9名) 4·實驗方法 塗布前處理受驗品,之後進行以貼膚測試受驗品為檢體的24 i讀㈣附讀。事先於受驗者的上臂關,以⑺隨施❿的 々圍X手‘不出3處及2處(兩手加起來5塊),使用㈣如 24 200815042 製的vapometer測量各處的經皮水份蒸散量。接著,將4種前處 理受驗品在每-處各塗布上1〇/zL,使其滲透5〜1〇分鐘左右(剩 下一處不塗布任何前處理受驗品)。在確認前處理受驗品已滲透進 皮膚之後’將大約20//L的貼膚受驗品滴於人體貼附實驗用貼布 Finn chamber (直徑π麵,大正製藥)上的濾紙,直接緊密貼附 在受驗者的5個標示處22小時。撕除貼布,於2小時後(貼附24 小牯後)及隔天的24小時後(貼附48小時後),依照表β所示的 ⑩判疋基準’目視觀祭皮膚反應的。同時測量經皮水分蒸散量。 [表6] 表6 本國基準 反應 評點 皮膚刺激評點平均值 二總評點和/受驗者數 — 沒反應 0 土 少許紅斑 0.5 + 明顯紅斑 1 + + 紅斑+浮腫、丘疹 2 + + + 紅斑+浮腫、丘療+小 水泡 3 + + + + 大水泡 4 5.目視判定結果 目視判定結果如表7所示。 沒有塗布前處理受驗品的情況下,貼附〇. 5%月桂基硫酸納水 溶液24小時後的皮膚刺激評點平均值為〇. 75G,根據塗布前處理 25 200815042 受驗品的情況,皮膚刺激評點平均值會降低。特別是,實施例^ 的油劑(0.208)、實施例3的乳霜(〇167)的刺激緩和效果非常 顯著’與沒有塗布前處理受驗品的情況她,皮㈣激評點平均 值降低為2/1G〜3/1G。比較例2的乳霜α 458)與沒有塗布前 處理受驗品的情況相比為6/1Q ’尚有刺激緩和效果,但流動石蝶 (0.667)與沒有塗布前處理受驗品的情況相比為9/1{),則幾乎 沒有刺激緩和效果。 沒有塗布前處理受驗品的情況下,貼附〇.5%月桂基硫酸納水 溶液48小時後的皮膚刺激評點平均值為1〇83。關於前處理受驗 品的塗布效果,實施例1的油劑(0·333)與沒有塗布前處理受驗 品的情況相比為3/10,因此可知具有顯著的刺激緩和效果。實施 例3的乳霜(〇· 583)與沒有塗布前處理受驗品的情況相比為5/ 10,是具有刺激緩和效果。比較例1的乳霜(〇.792)與沒有塗布 前處理受驗品的情況相比為7/1 〇,雖然較弱但仍具有刺激缓和效 果。另一方面,塗布流動石蠟時的皮膚刺激評點平均值為1292, 與沒有塗布前處理受驗品的情況相比為12/10,月桂基硫酸鈉的 刺激更為漸漸增強的結果。 因此可以確認實施例1的油劑、以及混合實施例1油劑的實 施例3的乳霜,皆具有顯著的刺激缓和作用。 26 200815042 [表7] 表7 本國基準 皮膚刺激 評點平均值 經皮水分蒸散量 g/(m2 · hr) 前處理 文驗品 貼膚試驗受 驗品 貼附24 小時後 貼附48 小時後 貼附24 小時後 貼附48 小時後 貼附24 小時後 貼附48 小時後 實施例1 的油劑 (DEG-DA5) 無菌水 ±1名 +1名 ±1名 0.125 0. 042 2 1 0.5%月桂基硫 酸鈉水溶液 ±5名 ±6名 +1名 0.208 0. 333 5 4 實施例3 乳霜 無菌水 ±1名 +1名 0名 0.125 0. 000 1 0.4 0. 5%月桂基硫 酸納水溶液 ±4名 ±6名 +4名 0.167 0. 583 4 4 流動石蠟 無菌水 ±3名 0名 0.125 0.000 2 2 0.5%月桂基硫 酸鈉水溶液 ±6名 +3名 ±1名 +11名 0.667 1.292 11 15 比較例2 乳霜 無菌水 ±3名 0名 0.125 0. 000 2 2 0· 5%月桂基硫 酸鈉水溶液 ±5名 +2名 ±5名1 +6名 0.458 0. 792 7 8 沒有塗布 無菌水 ±2名 +2名 ±2名 0. 250 0.083 3 2 〇· 5%月桂基硫 酸鈉水溶液 ±6名 +5名 土2名 +9名 0. 750 1.083 8 12 6·經皮水分蒸散量測量結果 經皮水分蒸散量測量結果如表7所示。 27 200815042 在沒有塗布前處理受驗品的情況下,貼附〇· 5%月桂基硫酸鈉 水溶液24小時後的經皮水分蒸散量為8,而貼附無菌水時的經皮 水分蒸散量為3,相比之下可以明顯知道皮膚隔離被破壞,皮膚更 加粗糙。藉由事先塗布實施例1的油劑、實施例3的乳霜,貼附 〇· 5%月桂基硫酸鈉水溶液24小時後的經皮水分蒸散量各為5及 4,相對沒有塗布前處理受驗品的8,可以抑制約一半的水分蒸散 量。 因此,能發揮刺激緩和效果及肌膚粗糙防止效果。在事先塗 布比較例1的乳霜的情況下,貼附0.5%月桂基硫酸鈉水溶液24 小日守後的經皮水分条散I為7’與沒有塗布前處理受驗品的8幾乎 ;又全,因此不具有刺激緩和效果及肌膚粗链防止效果。而事先塗 布流動石蠟的情況下,貼附0.5%月桂基硫酸鈉水溶液24小時後 的經皮水分蒸散量為11,是沒有塗布前處理受驗品δ的大約L 4 倍,皮膚刺激及肌膚粗糙度更為增強。 在沒有塗布前處理受驗品的情況下,貼附〇· 5%月桂基硫酸鈉 水溶液48小時後的經皮水分蒸散量增加到12,肌膚粗糙度持續嚴 重。藉由事先塗布實施例1的油劑、實施例3的乳霜,貼附〇· 5 %月桂基硫酸納水溶液48小時後的經皮水分蒸散量皆為4,為沒 有塗布前處理受驗品12的1/3。而且與沒有塗布前處理受驗品、 貼附無菌水48小時後的經皮水分蒸散量2之間的差異甚小。因 此,肌膚粗糙度沒有惡化尚屬輕微,明顯地可有效抑制肌膚粗糙。 28 200815042 在事先塗布比較例1的乳霜的情況下,貼附〇· 5%月桂基硫酸鈉水 溶液48小時後的經皮水分蒸散量為8,為沒有塗布前處理受驗品 12的2/3。雖具有肌膚粗糙防止效果,但卻不如實施例1的油劑、 實施例3的乳霜那般明顯。而事先塗布流動石蠟的情況下,貼附 0.5%月桂基硫酸鈉水溶液48小時後的經皮水分蒸散量為15,是 沒有塗布刚處理受驗品12的大約1· 3倍,皮膚刺激及肌膚粗糙度 更為增強。 ® 因此可以確認實施例1的油劑,以及混合實施例1的油劑的 實施例3的乳霜,皆具有顯著的刺激緩和作用及肌膚粗链防止效 果0For the oil agent of Example 1, the cream of the oil of Example 丨 (as Example 3), the liquid sarcophagus, and the cream of mixed mixed sarcophagus (Comparative Example), the skin test was used to evaluate the lauryl Sodium sulphate stimulating effect. 1. Pretreatment of the test article The oil agent of Example 1, the flow stone butterfly, and the cream of Example 3 and Comparative Example 1 composed of Table 5 were applied to the skin before being used for the test of the skin test. on. 2. Skin test test The 〇· 5% sodium lauryl sulfate aqueous solution and sterile water (sterilized) (as known) are used as skin-care products. 3. The subject, ... used in the previous skin test, for the sodium laurate sulfate 〇 〇 〇 水 水 水 壬 壬 壬 壬 壬 壬 壬 壬 壬 壬 壬 , , , , , , , , , , , , , , , , , , , , , , , , , 2〇~5〇 years old person's name ^ (3 males and 9 females) 4·Experimental method Pre-treatment of the test article, followed by the skin test test for the sample 24 i read (4) read. Before the subject's upper arm is closed, (7) with the application of the X-handler's no more than 3 places and 2 places (both hands add up to 5 pieces), use (4) such as 24 200815042 system vapometer to measure the percutaneous water everywhere The amount of evapotranspiration. Next, the four kinds of pretreated samples were coated with 1 〇/zL at each position, and allowed to permeate for about 5 to 1 minute (the remaining portion was not coated with any pretreated article). After confirming that the test article has penetrated into the skin, 'drop about 20//L of the skin test article on the filter paper attached to the human body patch Finn chamber (diameter π face, Taisho Pharmaceutical), directly close Attached to the subject's 5 markings for 22 hours. The patch was peeled off, and after 2 hours (after 24 hours of attachment) and 24 hours after the next day (after 48 hours of attachment), the skin reaction was visually observed according to the 10 criteria shown in Table β. The transepidermal water evapotranspiration was also measured. [Table 6] Table 6 National benchmark response evaluation Skin irritation evaluation mean 2 general evaluation points and / number of subjects - no response 0 soil a little erythema 0.5 + obvious erythema 1 + + erythema + edema, papules 2 + + + erythema + edema , Qiu treatment + small blisters 3 + + + + large blisters 4 5. Visual judgment results The visual judgment results are shown in Table 7. In the absence of pre-treatment of the test article, the average value of skin irritation after 5% sodium lauryl sulfate solution for 24 hours is 〇. 75G, according to the pre-coating treatment 25 200815042, the skin irritation The average rating will decrease. In particular, the oil-suppressing agent (0.208) of Example ^ and the cream (〇167) of Example 3 have a very significant effect of stimulating the mitigation of the test article, and the average value of the skin (4) stimuli is reduced to 2/1G~3/1G. The cream α 458) of Comparative Example 2 has a stimulating effect of 6/1Q as compared with the case where the pretreated sample is not coated, but the flow stone butterfly (0.667) is different from the case where the pretreatment sample is not coated. The ratio is 9/1{), and there is almost no irritating effect. In the case where the test article was not coated before application, the skin irritation evaluation value after attaching 〇.5% of sodium lauryl sulfate aqueous solution for 48 hours was 1〇83. Regarding the coating effect of the pretreated sample, the oil agent (0·333) of Example 1 was 3/10 as compared with the case where the sample was not coated before the coating, and therefore it was found to have a remarkable stimulating effect. The cream (〇·583) of Example 3 was 5/10 in comparison with the case where the test article was not coated before application, and it had a stimulating effect. The cream of Comparative Example 1 (〇.792) was 7/1 相比 as compared with the case where the pretreated sample was not coated, and although it was weak, it still had a stimulating effect. On the other hand, the average value of skin irritation when applying paraffin wax was 1292, which was 12/10 compared with the case where the test article was not coated, and the stimulation of sodium lauryl sulfate was gradually enhanced. Therefore, it was confirmed that the oil agent of Example 1 and the cream of Example 3 in which the oil agent of Example 1 were mixed had a remarkable stimulating effect. 26 200815042 [Table 7] Table 7 National standard skin irritation evaluation average percutaneous water evapotranspiration g/(m2 · hr) Pretreatment sample Skin test The test article is attached for 24 hours and attached for 48 hours. After 24 hours, after attaching for 48 hours, attach 24 hours and attach 48 hours after the oil of Example 1 (DEG-DA5). Sterile water ± 1 +1 + 1 0.125 0. 042 2 1 0.5% lauryl Sodium sulphate aqueous solution ± 5 ± 6 +1 + 0.208 0. 333 5 4 Example 3 Cream sterile water ± 1 +1 0 0 0.125 0. 000 1 0.4 0. 5% sodium lauryl sulfate aqueous solution ± 4 Name ± 6 + 4 0.167 0. 583 4 4 Flowing paraffin sterile water ± 3 0 0 0.125 0.000 2 2 0.5% sodium lauryl sulfate solution ± 6 + 3 ± 1 + 11 0.667 1.292 11 15 Compare Example 2 Cream sterile water ± 3 0 0 0.15 0. 000 2 2 0 · 5% aqueous solution of sodium lauryl sulfate ± 5 + 2 ± 5 1 + 6 0.485 0. 792 7 8 No coated sterile water ± 2 + 2 + 2 0. 250 0.083 3 2 〇 · 5% aqueous solution of sodium lauryl sulfate ± 6 + 5 soil 2 + 9 0. 750 1.083 8 12 6 · Transdermal moisture evapotranspiration measurement results Skin water evaporation measurement results are shown in Table 7. 27 200815042 In the case where the test article is not treated before coating, the transdermal moisture evapotranspiration after attaching 〇·5% sodium lauryl sulfate aqueous solution for 24 hours is 8 and the transdermal moisture evapotranspiration when the sterile water is attached is 3, in contrast, it can be clearly seen that the skin isolation is destroyed and the skin is rougher. By applying the oil agent of Example 1 and the cream of Example 3 in advance, the transdermal moisture evapotranspiration after attaching the 5% 5% sodium lauryl sulfate aqueous solution for 24 hours was 5 and 4, respectively. At the inspection of 8, it can suppress about half of the water evapotranspiration. Therefore, it is possible to exert a stimulating effect and a skin roughness preventing effect. In the case where the cream of Comparative Example 1 was applied in advance, the percutaneous moisture strip I of the 0.5% sodium lauryl sulfate aqueous solution was attached for 24 hours, and the peeling I of the test article was almost 7; It is full, so it does not have a stimulating effect and a skin thick chain preventing effect. When the paraffin wax was applied in advance, the transdermal moisture evapotranspiration after attaching the 0.5% sodium lauryl sulfate aqueous solution for 24 hours was 11 times, which was about L 4 times that of the pretreatment coated product δ, skin irritation and rough skin. The degree is even stronger. In the case where the test article was not treated before coating, the transdermal moisture evapotranspiration after the 〇·5% sodium lauryl sulfate aqueous solution was applied for 48 hours was increased to 12, and the skin roughness was continued to be severe. By applying the oil agent of Example 1 and the cream of Example 3 in advance, the transdermal moisture evapotranspiration after the 〇·5 % sodium lauryl sulfate aqueous solution was applied for 48 hours was 4, which was the pretreatment without the coating. 1/3 of 12. Moreover, the difference between the transepidermal water evapotranspiration amount 2 after 48 hours from the application of the test article without the pre-coating treatment and the attachment of the sterile water was small. Therefore, the roughness of the skin is not deteriorated, and it is obvious that it can effectively inhibit the roughness of the skin. 28 200815042 When the cream of Comparative Example 1 was applied in advance, the transdermal moisture evapotranspiration after the 〇·5% sodium lauryl sulfate aqueous solution was applied for 48 hours was 8, which was 2/ of the pretreatment sample 12 without coating. 3. Although it had a skin roughness preventing effect, it was not as noticeable as the oil agent of Example 1 and the cream of Example 3. When the paraffin wax was applied in advance, the transdermal moisture evapotranspiration after the application of the 0.5% sodium lauryl sulfate aqueous solution for 48 hours was 15 times, which was about 1.3 times that of the newly treated test article 12, skin irritation and skin. The roughness is more enhanced. Therefore, it was confirmed that the oil of Example 1 and the cream of Example 3 in which the oil of Example 1 were mixed all had significant irritation and relaxation effects and skin thick chain prevention effect.

行刺激緩和效果實驗> 利用人類貼膚測試驗證實施例!的油劑(DEG—Μ5)、混合了 DEG M5的礼相’其對患有異位性皮膚炎或皮脂缺乏症的受驗者 的驗證刺激緩和效果。 1.受驗者 1 一 1年齡構成 年齡在19歲〜45歲之間的男性2〇位,平均年齡為27. 9歲, 且在實驗途中無人退出。 1一2受驗者的皮膚疾病 事前請實驗的貞責醫生針對受驗麵症狀進行診斷。患有異 29 200815042 位性皮膚炎的受驗者有11位、皮脂缺乏症者有9位。患有異位性 皮膚炎的受驗者中,有7位症狀較輕,輕微〜中等有2位,2位症 狀中等。 2·前處理受驗品將實施例1的油劑、混有實施例1的油劑的3種 乳霜、以及作為比較例一般皆用來作為化妝品用油劑,混有流動 石蝶及鯊烯的乳霜共4種、以及皮膚科經常用來作為保濕劑的凡 士林,做為前處理受驗品,並以沒有處理作為對照組。 (1) 混有20%DEG—DA5之實施例3的乳霜 (2) 混有10%DEG—DA5之實施例4的乳霜 (3) 混有5%DEG—DA5之實施例5的乳霜 (4) 混有20%流動石蠟之比較例1的乳霜 (5) 混有10%流動石蠟之比較例3的乳霜 (6) 混有20%鯊烯之比較例2的乳霜 (7) 混有10%鯊稀之比較例4的乳霜 (8) 實施例1的油劑(DEG—DA5) (9) 甘油(曰興理化製) (10) 無處理(對照) 實施例3、錄例卜2的乳霜處方如表5所示;實施例4、5、 比較例3、4的乳霜處方如表8所示。 全性實驗 為了進行前處理_安全性賴實驗,必須實施24小時的密 200815042 著貼膚測試。貼附的4種受驗物質[混有2〇%DEG—DA5的乳霜(實 施例3)、混有20%流動石蠟的乳霜(比較例1 )、混有2〇%鯊烯 的乳霜(比較例2)、凡士林]的目視評價結果示於表μ。混有deg 一DA5的乳霜及混有流動石躐的乳霜,在各個判定時間皆呈全陰性 ^ 的結果,相對於此混有鯊烯的乳霜在24h判定時有1名受驗者呈 現點數3 ’混有凡士林則在24h判定時有1名受驗者呈現點數1。 然而,在48h、第7天後的刺激反應皆呈現降低,並確認沒有出現 _ 過敏症狀。藉由以上的結果,可以確認4種受驗物質經過24h閉 基貼附的結果’明顯不會引發皮膚一次刺激性。Line stimulation mitigation effect experiment> Validation of the example using the human skin test! The oil agent (DEG-Μ5), a courtesy of DEG M5, has a stimulating and stimulating effect on a subject suffering from atopic dermatitis or sebum deficiency. 1. Subjects 1 - 1 age composition Males between the ages of 19 and 45 are 2, the average age is 27.9 years old, and no one withdraws during the experiment. 1 to 2 skin diseases of the subject Beforehand, please consult a doctor who is responsible for the diagnosis of the symptoms of the face. There were 11 subjects with different dermatitis 2008, and 9 with sebum deficiency. Among the subjects with atopic dermatitis, 7 had mild symptoms, mild to moderate with 2, and 2 with moderate symptoms. 2. Pretreatment of the test article The oil agent of Example 1, the three types of cream mixed with the oil agent of Example 1, and the comparative example are generally used as a cosmetic oil agent mixed with a flowing stone butterfly and a shark. A total of 4 kinds of enamel creams, and Vaseline, which is often used as a moisturizer in dermatology, as a pre-treatment test, and no treatment as a control group. (1) Cream of Example 3 mixed with 20% DEG-DA5 (2) Cream of Example 4 mixed with 10% DEG-DA5 (3) Milk of Example 5 mixed with 5% DEG-DA5 Cream (4) Cream of Comparative Example 1 mixed with 20% of flowing paraffin (5) Cream of Comparative Example 3 mixed with 10% of flowing paraffin (6) Cream of Comparative Example 2 mixed with 20% of squalene ( 7) Cream of Comparative Example 4 mixed with 10% shark (8) Oil of Example 1 (DEG-DA5) (9) Glycerin (manufactured by Daisei Chemical Co., Ltd.) (10) No treatment (control) Example 3 The cream prescription of the example 2 is shown in Table 5; the cream prescriptions of Examples 4 and 5 and Comparative Examples 3 and 4 are shown in Table 8. Full-scale experiment In order to carry out the pre-treatment _ safety reliance experiment, a 24-hour secret 200815042 skin test must be implemented. 4 kinds of test substances to be attached [cream mixed with 2% DEG-DA5 (Example 3), cream mixed with 20% mobile paraffin (Comparative Example 1), milk mixed with 2% squalene The visual evaluation results of the cream (Comparative Example 2) and Vaseline] are shown in Table μ. The cream mixed with deg-DA5 and the cream mixed with the mobile sarcophagus were all negative at each determination time. Compared with the squalene cream, there was one subject at 24h. The number of points presented is 3'. When Vaseline is mixed, one subject presents a point of 1 at the time of judgment at 24h. However, the stimulatory response was reduced after 48 h and the 7th day, and it was confirmed that there was no _ allergy symptom. From the above results, it was confirmed that the results of the attachment of the four test substances to the closed cells for 24 hours were not significantly irritating to the skin.

31 200815042 [表8] 表8 實施例4 實施例5 比較例3 比較例4 油 劑 實施例1的油劑(DEG-DA5 ) 10.0 5.0 流動石蠟 10.0 鯊烯 10.0 油 劑 以 外 的 成 分 山荼醇 3.0 3.0 3.0 3.0 甘油 30.0 30· 0 30.0 30.0 1,3-丁二醇 4.0 4.0 4.0 4.0 麥芽糖醇 0.4 0.4 0.4 0.4 瑕紅素 0.1 0.1 0.1 0.1 羧乙烯基聚合物 0.5 0.5 0.5 0.5 三仙膠 0.1 0.1 0.1 0.1 單硬脂酸十聚甘油酯 1.0 1.0 1.0 1.0 精胺酸 0.5 0.5 0.5 0.5 水 殘留 殘留 殘留 殘留 3·貼膚測試受驗品 為了進行皮膚一次刺激緩和效果的評價,將皮膚刺激物質之 0.5%月桂基硫酸鈉(關東化學)水溶液(以下簡稱SLS)作為貼 膚測試受驗品。於各個塗布部位同時貼附無菌水作為對照。 4·變法密著貼膚測試實驗方法 在受驗者的背部使用塑膠框以10mmx30mm的面積設定10處, 將貝施例1的油劑(DEG—DA5)、甘油及實施例3〜5、比較例1〜 32 3 200815042 4的乳霜’细微量分注器分棚取—固定份量(約π处),1 處塗布1種讀理受驗品,前處理受驗品的塗布區域共有9處, 剩餘的1處則是未處理區以作為對照組。 之後’將皮膚刺激物質之〇.5%月桂基硫酸鈉(SLS)及對昭 -組的無菌水作為貼膚測試受驗品,實施24小時的密著貼膚測試;: 貼膚測試中使用的是大正製藥的Finn貼布。 β塗布部位可選擇背骨左右各5處,並由實驗的負責醫生巡視 ❿受驗者的背部,避開紅斑等發炎部位來進行前處理受驗品的塗 布、貼附藥布。 5·評價項目及評價時間 針對以下2項目進行評價。 ο皮膚所見:藉由貼膚測試所引起的皮膚變化的目視判定(實驗 第2天、第3天、第7天) 2)理學檢查:利用va卿ter〇)elfin)測量經表皮水分蒸散量(實 _驗第2天、第3天) 6.評價方法 6.1皮膚所見 目視判定係以皮膚刺激判定基準(表9 )為準,由實驗負責 醫生來進行。判定結果以評點換算出平均值,將得到的數值與無 塗布部、凡士林塗布部做一比較,並判斷其有效性。 33 200815042 [表9] 表9 皮膚刺教判定某準 評點 皮膚反應 0 無紅斑反應 1 只有少許紅斑 2 紅斑色調比1更明顯,且紅斑面積達5〇% 3 明顯紅斑 4 紅斑+丘疹•浮腫 5 紅斑+小水泡 6 大水泡•壞死31 200815042 [Table 8] Table 8 Example 4 Example 5 Comparative Example 3 Comparative Example 4 Oil agent Oil agent of Example 1 (DEG-DA5) 10.0 5.0 Flowing paraffin 10.0 Squalene 10.0 In addition to the oil agent, behenyl alcohol 3.0 3.0 3.0 3.0 Glycerin 30.0 30· 0 30.0 30.0 1,3-Butanediol 4.0 4.0 4.0 4.0 Maltitol 0.4 0.4 0.4 0.4 Alizarin 0.1 0.1 0.1 0.1 Carboxyvinyl polymer 0.5 0.5 0.5 0.5 Sanxianjiao 0.1 0.1 0.1 0.1 Decaglyceryl monostearate 1.0 1.0 1.0 1.0 arginine 0.5 0.5 0.5 0.5 Residual residue of water residue 3. Skin test The test article is used to evaluate the irritating effect of skin irritation, 0.5% laurel of skin irritant A sodium sulfate (Kanto Chemical) aqueous solution (hereinafter referred to as SLS) is used as a skin test test. Sterile water was simultaneously attached to each of the coated sites as a control. 4·Modification and close-fitting test method The test method is to use a plastic frame on the back of the subject to set 10 areas of 10 mm×30 mm, and compare the oil agent (DEG-DA5) of Example 1 with glycerin and Examples 3 to 5. Example 1~ 32 3 200815042 4 cream 'fine micro-dispenser split to take a fixed amount (about π), 1 place to apply a type of reading test, pre-treatment of the test article has a total of 9 areas The remaining 1 is the untreated area as a control group. After that, the skin irritant substance, 5% sodium lauryl sulfate (SLS) and the sterile water of the group, were used as a skin test, and a 24-hour close-fitting test was carried out; It is the Finn patch of Taisho Pharmaceuticals. The β-coated part can be selected from the left and right sides of the back bone, and the doctor in charge of the experiment inspects the back of the subject, avoiding the inflamed area such as erythema, and pre-treating the coated article and attaching the medicated cloth. 5. Evaluation items and evaluation time The following two items were evaluated. οWhat the skin sees: visual judgment of skin changes caused by skin test (experimental day 2, day 3, day 7) 2) Physical examination: measurement of transepidermal water evapotranspiration using vaqingter〇)elfin) (Establishment Day 2, Day 3) 6. Evaluation Method 6.1 The visual judgment of the skin was based on the skin irritation criterion (Table 9), and was performed by the doctor in charge of the experiment. The judgment result was averaged by the evaluation point, and the obtained value was compared with the non-coating section and the Vaseline coating section, and the validity was judged. 33 200815042 [Table 9] Table 9 Skin sputum determines a quasi-reported skin reaction 0 No erythema reaction 1 Only a little erythema 2 Red spot is more pronounced than 1 and erythema area is 5〇% 3 Obvious erythema 4 erythema + pimples • Puffy 5 Erythema + small blisters 6 large blisters • necrosis

6· 2理學檢查 利用vapometer所得到的經表皮水分蒸散量測量值,係以各 貼布貼附部位與無貼附部位之間的差值來進行解析,並將各個受 驗物質塗布部位的數值與無塗布部、凡士林塗布部做一比較,來 •判斷其有效性。 7·經由皮膚科醫師目視判定 於貼附24小時後、48小時後、第7天,基於皮膚刺激基準由 實驗的負責醫師以目視判定,貼附24小時後的目視判定結果如表 10所示,貼附48小時後的目視判定結果如表11所示。圖3、圖4 係表示在各前處理劑的20名受驗者〇. 5%月桂基硫酸鈉水溶液 (SLS)皮膚刺激的點數中,只挑出皮膚刺激基準點數為3、4,在經 過24小時後、48小時後的總和人數。其中,沒有受驗者的皮膚刺 34 200815042 激基準點數超過4。 在24小日守後的判疋中,和無塗布部位相較之下,於da5 塗布α(Μ立(實施例1)、混有20%DEG-DA5的乳霜(實施例3)塗 布部位,目視评價點數呈現3、4以上的受驗者明顯為少數,接著 是混有10%DEG—DA5的乳霜(實施例4)、混有5%DEG—Μ5的乳 霜(實施例5)。凡士林在〇·5%月桂基硫酸鈉水溶液(SLS)貼附 後的目視評價點數呈現3、4以上的受驗者為5人,和無塗布部位 馨的12人相較之下,結果雖然算少,但與DEG—DA5及混有DEG—DA5 的乳霜相比之下,人數還是偏多。若將混有DEG一Μ5者由點數1 以上的合計點數而言,則能斷定全體可緩和刺激,此外,同樣能 斷定如上所述呈現刺激較強烈、點數3以上的人數也算少。 依照Wilcoxon符號順位總和檢定的結果,職一M5塗布部位 (實施例1)、混有20%0£0~〇八5的乳霜(實施例3)塗布部位、 混有10%DEG—DA5的乳霜(實施例4)塗布部位,與凡士林塗布 ⑩部位相較之下,點數較低(Ρ<〇· 05)。混有5%DEG—DA5的乳霜(實 施例5)則#不出明顯抑制傾向。又,混有2〇%DEG—DA5的乳霜 (實施例3),與混有20%流動石蠟的乳霜(比較例1 )、混有2〇 %鯊烯的乳霜(比較例2)相較之下,明顯較能抑制刺激點數。此 外,混有10%DEG-DA5的乳霜(實施例4),與混有1〇%流動石 躐的乳霜(比較例3)、混有10%鯊烯的乳霜(比較例4)相較之 下,也明顯較能抑制刺激點數。 35 200815042 在48小時後的判定中,和無塗布部位相較之下,deg—M5 塗布部位、混有5%DEG-DA5的乳霜(實施例5)塗布部位,目視 [貝點數主現3、4以上的受驗者明顯為少數,接著是混有2〇%deg —M5的乳霜(實施例3)、混有20%流動石徵的乳霜(比較例1)。 凡士林在SLS貼附後的目視評價點數呈現3、4以上的受驗者為8 人,和無塗布部位的15人相較之下,結果雖然算少,但與DEG_ M5及混有DEG—DA5的乳霜相較之下,人數還是偏多。 依照Wilcoxon符號順位總和檢定的結果,DEG—M5塗布部位 (實施例1)、混有20%DEG-DA5的乳霜(實施例3)塗^位、 混有5%DEG-DA5的乳霜(實施例5)塗布部位,與凡士林塗布部 位相較之下,點數較低(p<G. 〇5)。又,混有2Q%deg—廳的乳 霜(實施例3) ’與混有20%f烯的乳霜(比較例2)她之下, 明顯較能抑制刺激點數(Ρ<0· 05)。 第7天的判定係為了確認有無過敏症狀所實施的。其結果為, 點數呈現1以上的受驗者只有1位,是在無塗布部位的SLS貼附 部位,前處理劑是沒有影響的。 36 200815042 [表 10] 表1G 24h目視判定 (人) no· 前處理樣本 貼布 點數 樣本 0 1 2 3 4 5 6 1 DEG-DA5 20%乳霜(實施例3) SLS 13 5 1 1 0 0 0 2 DEG-DA5 20%乳霜(實施例3) 水 18 2 0 0 0 0 0 3 鯊烯20%乳霜(比較例2) SLS 7 3 3 5 2 0 0 4 鯊烯20%乳霜(比較例2) 水 17 3 0 0 0 0 0 5 DEG-DA5 10%乳霜(實施例4) SLS 11 5 1 2 1 0 0 6 DEG-DA5 10%乳霜(實施例4) 水 19 1 0 0 0 0 0 7 DEG-DA5 100% (實施例 1) SLS 16 3 0 0 1 0 0 8 DEG-DA5 100% (實施例 1) 水 18 2 0 0 0 0 0 9 DEG-DA5 5%乳霜(實施例5) SLS 10 4 2 2 2 0 0 10 DEG-DA5 5%乳霜(實施例5) 水 19 1 0 0 0 0 0 11 流動石蠟20%乳霜(比較例1) SLS 8 4 4 2 2 0 0 12 流動石蠟20%乳霜(比較例1) 水 19 0 1 0 0 0 0 13 鯊烯10%乳霜(比較例4) SLS 6 4 1 8 1 0 0 14 鯊烯10%乳霜(比較例4) 水 19 1 0 0 0 0 0 15 流動石蠟10%乳霜(比較例3) SLS 5 5 2 6 2 0 0 16 流動石蠟10%乳霜(比較例3) 水 19 0 1 0 0 0 0 17 凡士林 SLS 4 5 6 4 1 0 0 18 凡士林 水 20 0 0 0 0 0 0 19 無塗布 SLS 1 4 3 9 3 0 0 20 無塗布 水 15 3 1 0 1 0 0 37 200815042 [表 11] 表11 48h目視判定 (人) no. 前處理樣本 貼布 樣本 點數 0 1 2 3 4 5 6 1 DEG-DA5 20%乳霜(實施例3) SLS 10 5 1 3 1 0 0 2 DEG-DA5 20%乳霜(實施例3) 水 19 1 0 0 0 0 0 3 鯊烯20%乳霜(比較例2) SLS 2 5 7 6 0 0 0 4 鯊烯20%乳霜(比較例2) 水 18 2 0 0 0 0 0 5 DEG-DA5 10%乳霜(實施例4) SLS 4 8 2 6 0 0 0 6 DEG-DA5 10%乳霜(實施例4) 水 20 0 0 0 0 0 0 7 DEG-DA5 1M% (實施例 1) SLS 14 4 0 2 0 0 0 8 DEG-DA5 100% (實施例 1) 水 19 0 1 0 0 0 0 9 DEG-DA5 5%乳霜(實施例5) SLS 3 10 4 3 0 0 0 10 DEG-DA5 5%乳霜(實施例5) 水 19 0 1 0 0 0 0 11 流動石蠟20%乳霜(比較例1) SLS 3 5 8 4 0 0 0 12 流動石蠟20%乳霜(比較例1) 水 18 2 0 0 0 0 0 13 鯊烯10%乳霜(比較例4) SLS 2 5 4 9 0 0 0 14 鯊烯10%乳霜(比較例4) 水 19 1 0 0 0 0 0 15 流動石蠟10%乳霜(比較例3) SLS 4 1 4 11 0 0 0 16 流動石蠟10%乳霜(比較例3) 水 18 1 1 0 0 0 0 17 凡士林 SLS 1 6 5 6 2 0 0 18 凡士林 水 19 1 0 0 0 0 0 19 無塗布 SLS 0 2 3 13 2 0 0 20 無塗布 水 17 2 1 0 0 0 0 38 200815042 [表 12] 前處理劑之安全性確認試驗結果6. 2 Physical examination The measured value of the transepidermal water evapotranspiration obtained by the vapometer is analyzed by the difference between the patch attachment portion and the non-attachment portion, and the coated portion of each test substance is applied. The value is compared with the non-coating section and the Vaseline coating section to determine the effectiveness. 7. Visually judged by the dermatologist 24 hours after, 48 hours, and 7 days after the attachment, the visual judgment was judged by the responsible physician based on the skin irritation standard, and the visual judgment results after 24 hours of attachment were as shown in Table 10. The results of the visual judgment after 48 hours of attachment are shown in Table 11. Fig. 3 and Fig. 4 show that among the 20 subjects of each pretreatment agent 〇. 5% sodium lauryl sulfate aqueous solution (SLS) skin irritation, only the skin irritation reference points were 3, 4, The total number of people after 24 hours and 48 hours. Among them, there is no skin thorn of the subject 34 200815042 The number of benchmark points exceeds 4. In the judgment of 24 hours after the sputum, the application of the cream (Example 1) and the cream containing 20% DEG-DA5 (Example 3) was applied to da5 in comparison with the uncoated portion. The subjects who visually evaluated the number of points of 3 or more were significantly fewer, followed by a cream mixed with 10% DEG-DA5 (Example 4) and a cream mixed with 5% DEG-Μ5 (Examples) 5) The number of visual evaluation points of Vaseline after 5% 5% sodium lauryl sulfate aqueous solution (SLS) is 5 or more, compared with 12 people without coating. Although the result is small, compared with DEG-DA5 and the cream mixed with DEG-DA5, the number is still too large. If the number of points mixed with DEG Μ5 is more than 1 point, It can be concluded that all the mitigating stimuli can be determined. In addition, it can be concluded that the number of people who have strong stimuli as described above and the number of points is 3 or more is also small. According to the result of the Wilcoxon symbol summation test, the job M5 coating site (Example 1) 20% 0£0~〇8 5 cream (Example 3) coated part, 10% DEG-DA5 cream (Example 4) coated part, and Vaseline Compared with the 10 parts coated, the number of points is lower (Ρ < 〇 · 05). The cream mixed with 5% DEG-DA5 (Example 5) # does not show a significant inhibition tendency. Also, mixed 2% The cream of DEG-DA5 (Example 3) was significantly better than the cream mixed with 20% of paraffin wax (Comparative Example 1) and the cream mixed with 2% squalene (Comparative Example 2). The number of stimulating points can be suppressed. In addition, a cream containing 10% DEG-DA5 (Example 4), a milk mixed with 1% of mobile sarcophagus (Comparative Example 3), and milk mixed with 10% squalene In comparison with the cream (Comparative Example 4), the number of stimulation points was also significantly suppressed. 35 200815042 In the judgment after 48 hours, the deg-M5 coating site was mixed with 5% DEG compared with the uncoated portion. -DA5 cream (Example 5) Applicable site, visual inspection [The number of subjects with 3 or more bene points is obviously a minority, followed by a cream mixed with 2% deg - M5 (Example 3) Cream with 20% mobile stone sign (Comparative Example 1). The number of visual evaluation points of Vaseline after SLS attachment is 3 or more, and 8 persons are compared with 15 people without coating. Below, the results are small, but with DEG_ Compared with the cream with DEG-DA5, the number of M5 is still too large. According to the results of the Wilcoxon symbol summation test, the DEG-M5 coating site (Example 1), a cream mixed with 20% DEG-DA5 (Example 3) The application site of the cream (Example 5) coated with 5% DEG-DA5 was coated, and the number of dots was lower than that of the Vaseline coated portion (p < G. 〇 5). , mixed with 2Q% deg-room cream (Example 3) 'With a cream mixed with 20% f-ene (Comparative Example 2), she was significantly more able to suppress the number of stimulation points (Ρ <0· 05) . The judgment on the 7th day was carried out in order to confirm the presence or absence of allergy symptoms. As a result, there was only one subject having one or more points, and the SLS attachment site was not applied, and the pretreatment agent had no effect. 36 200815042 [Table 10] Table 1G 24h visual judgment (person) no· pre-treatment sample patch point sample 0 1 2 3 4 5 6 1 DEG-DA5 20% cream (Example 3) SLS 13 5 1 1 0 0 0 2 DEG-DA5 20% cream (Example 3) Water 18 2 0 0 0 0 0 3 Squalene 20% cream (Comparative Example 2) SLS 7 3 3 5 2 0 0 4 Squalene 20% cream ( Comparative Example 2) Water 17 3 0 0 0 0 0 5 DEG-DA5 10% cream (Example 4) SLS 11 5 1 2 1 0 0 6 DEG-DA5 10% cream (Example 4) Water 19 1 0 0 0 0 0 7 DEG-DA5 100% (Example 1) SLS 16 3 0 0 1 0 0 8 DEG-DA5 100% (Example 1) Water 18 2 0 0 0 0 0 9 DEG-DA5 5% cream (Example 5) SLS 10 4 2 2 2 0 0 10 DEG-DA5 5% cream (Example 5) Water 19 1 0 0 0 0 0 11 Flowing paraffin 20% cream (Comparative Example 1) SLS 8 4 4 2 2 0 0 12 Flowing paraffin 20% cream (Comparative Example 1) Water 19 0 1 0 0 0 0 13 Squalene 10% cream (Comparative Example 4) SLS 6 4 1 8 1 0 0 14 Squalene 10% milk Cream (Comparative Example 4) Water 19 1 0 0 0 0 0 15 Flowing paraffin 10% cream (Comparative Example 3) SLS 5 5 2 6 2 0 0 16 Flowing paraffin 10% cream (Comparative Example 3) Water 19 0 1 0 0 0 0 17 Vaseline SLS 4 5 6 4 1 0 0 18 Vaseline Water 20 0 0 0 0 0 0 19 No coating SLS 1 4 3 9 3 0 0 20 No coating water 15 3 1 0 1 0 0 37 200815042 [Table 11] Table 11 48h visual judgment (person) no . Pretreatment Sample Patch Sample Points 0 1 2 3 4 5 6 1 DEG-DA5 20% Cream (Example 3) SLS 10 5 1 3 1 0 0 2 DEG-DA5 20% Cream (Example 3) Water 19 1 0 0 0 0 0 3 Squalene 20% cream (Comparative Example 2) SLS 2 5 7 6 0 0 0 4 Squalene 20% cream (Comparative Example 2) Water 18 2 0 0 0 0 0 5 DEG -DA5 10% cream (Example 4) SLS 4 8 2 6 0 0 0 6 DEG-DA5 10% cream (Example 4) Water 20 0 0 0 0 0 0 7 DEG-DA5 1M% (Example 1 SLS 14 4 0 2 0 0 0 8 DEG-DA5 100% (Example 1) Water 19 0 1 0 0 0 0 9 DEG-DA5 5% cream (Example 5) SLS 3 10 4 3 0 0 0 10 DEG-DA5 5% cream (Example 5) Water 19 0 1 0 0 0 0 11 Flowing paraffin 20% cream (Comparative Example 1) SLS 3 5 8 4 0 0 0 12 Flowing paraffin 20% cream (Comparative example) 1) Water 18 2 0 0 0 0 0 13 Squalene 10% cream (Comparative Example 4) SLS 2 5 4 9 0 0 0 14 Squalene 10% cream (Comparative Example 4) Water 19 1 0 0 0 0 0 15 mobile paraffin 10% cream (Comparative Example 3) SLS 4 1 4 11 0 0 0 16 Flowing paraffin 10% cream (Comparative Example 3) Water 18 1 1 0 0 0 0 17 Vaseline SLS 1 6 5 6 2 0 0 18 Vaseline water 19 1 0 0 0 0 0 19 None Coating SLS 0 2 3 13 2 0 0 20 No coating water 17 2 1 0 0 0 0 38 200815042 [Table 12] Safety confirmation test results of pretreatment agent

利用機器測量經表皮水分蒸散量 表13、圖5、圖6係表示各受驗物質的經表皮水分蒸散量的 平均值。在貼附24h後,於SLS貼附部位認定對於該刺激性具有 TEWL值抑制傾向的部份為DEG_DA5(實施例1)、混有2〇%deg_da5 的乳霜(實施例3)、混有l〇%DEG-DA5的乳霜(實施例4)。而混 有20%DEG-DA5的乳霜(實施例3)、混有1〇%deG-DA5的乳霜(實 施例4)對於無塗布部位,或是混有20%DEG—DA5的乳霜(實施例 3)對於凡士林塗布部位,皆可認定具有刺激抑制效果〇5)。 貼附48h後,在所有前處理劑中,和無塗布部位相較之下,皆能 有效抑制由於SLS貼附所引起的TEWL值上升(ρ<〇· 05)。特別是 DEG-DA5 (實施例1)、混有20%DEG_M5的乳霜(實施例3)和凡 士林塗布部位相較之下,也更能有效抑制(p<〇 〇5)。 39 200815042 [表 13] 表13各受驗物質之經表皮水分蒸散量值 no· 前處理樣本 貼布 樣本 24h 平均值 24h stdev 48h 平均值 48h stdev 1 DEG-DA5 20%乳霜(實施例3) SLS 5.8 5.2 4.0 3.5 2 DEG-DA5 20°/Γ乳霜(實施例3) 水 2.4 4.7 LI 3.2 3 鯊烯20%乳霜(比較例2) SLS 9.1 8.3 9.8 7.4 4 鯊烯20%乳霜(比較例2) 水 1.3 4.2 0.4 3.7 5 DEG-DA5 10%乳霜(實施例4) SLS 6.7 7.1 7.1 6.5 6 DEG-DA5 10%乳霜(實施例4) 水 1.0 2.3 0.8 3.2 7 DEG-DA5 100% (實施例 1) SLS 6.3 14.2 4.9 7.8 8 DEG-Μ5 100% (實施例 1) 水 2.4 5.4 1.3 4.3 9 DEG-DA5 5%乳霜(實施例5) SLS 8.3 10.5 7.5 8.2 10 DEG-Μ5 5%乳霜(實施例5) 水 2.3 4.3 1.6 4.2 11 流動石蠟20%乳霜(比較例1) SLS 8.9 10.0 6.9 5.1 12 流動石蠟20%乳霜(比較例1) 水 0.6 2.9 0.2 3.5 13 鯊烯10%乳霜(比較例4) SLS 9.1 7.7 9.5 6.9 14 鯊烯10%乳霜(比較例4) 水 1.8 4.4 0.7 3.4 15 流動石蠟10%乳霜(比較例3) SLS 8.0 7.2 8.3 5.9 16 流動石蠟10%乳霜(比較例3) 水 1.3 3.6 0.1 1.8 17 凡士林 SLS 9.4 8.1 10.2 5.9 18 凡士林 水 1.4 3.9 1.3 3.1 19 無塗布 SLS 11.8 8.2 15.8 7.8 20 無塗布 水 0.4 3.6 0.9 3.5 200815042 13.總結 本實驗中,在將DEG-DA5及配合DEG-DA5的乳霜的刺激成分 滲透抑制效果,利用20位患有異位性皮膚炎、皮脂缺乏症的為對 象進行驗證。其結果可知DEG-DA5及配合DEG—的乳霜,具有 依賴不同的濃度抑制SLS刺激的傾向,並且顯示出使用於人類時 能發揮效果的濃度為何。 _ 又’根據24小時的密著貼膚測試,可確認DEG—DA5及混有 DEG-M5魏霜職錄皮膚炎患者、皮麟乏症患者的安全性。 _以上的結果,可轉知混有DEG-DA5的錄料,非常適 合使用於隔離機能低下之異雜皮歧患者、皮麟乏症患者。 【圖式簡單說明】 圖1為將不含有月桂基破酸納的乳霜,於各種濃度下暴露在細胞時 #的生存率。 圖2為將含有〇. 1%濃度月桂基硫酸鈉的乳霜,於各種濃度下暴露 在細胞時的生存率。 圖3為為經過24小時的判定後’成績表示在3, 4的受試者的總和。 圖4為為經過48小時的判定後’成績表示在3,4的受試者的總和。 圖5為貼附24h後的經表皮水分蒸散量平均值(平均值士s D.)。 圖6為貼附48h後的經表皮水分蒸散量平均值(平均健.d.)。 41 200815042 【主要元件符號說明】Measurement of transepidermal water evapotranspiration by machine Table 13, Fig. 5, and Fig. 6 show the average value of the transepidermal water evapotranspiration amount of each test substance. After the attachment for 24 hours, it was confirmed that the part having the TEWL value inhibition tendency for the irritant was DEG_DA5 (Example 1) and the cream mixed with 2〇% deg_da5 at the SLS attachment site (Example 3), mixed with 〇% DEG-DA5 cream (Example 4). The cream mixed with 20% DEG-DA5 (Example 3), the cream mixed with 1% deG-DA5 (Example 4) for the uncoated part, or the cream mixed with 20% DEG-DA5 (Example 3) It was confirmed that the Vaseline coated portion had a stimulus inhibiting effect 〇 5). After 48 hours of attachment, the increase in TEWL value due to SLS attachment was effectively suppressed in all pretreatment agents compared to the uncoated portion (ρ < 〇 · 05). In particular, DEG-DA5 (Example 1), a cream mixed with 20% DEG_M5 (Example 3) was more effectively inhibited (p<〇5) than the V. sinensis coated site. 39 200815042 [Table 13] Table 13 Transdermal moisture evapotranspiration values of each test substance no· Pretreatment sample patch sample 24h Average 24h stdev 48h Average 48h stdev 1 DEG-DA5 20% cream (Example 3) SLS 5.8 5.2 4.0 3.5 2 DEG-DA5 20°/Γ cream (Example 3) Water 2.4 4.7 LI 3.2 3 Squalene 20% cream (Comparative Example 2) SLS 9.1 8.3 9.8 7.4 4 Squalene 20% cream ( Comparative Example 2) Water 1.3 4.2 0.4 3.7 5 DEG-DA5 10% cream (Example 4) SLS 6.7 7.1 7.1 6.5 6 DEG-DA5 10% cream (Example 4) Water 1.0 2.3 0.8 3.2 7 DEG-DA5 100 % (Example 1) SLS 6.3 14.2 4.9 7.8 8 DEG-Μ5 100% (Example 1) Water 2.4 5.4 1.3 4.3 9 DEG-DA5 5% cream (Example 5) SLS 8.3 10.5 7.5 8.2 10 DEG-Μ5 5 % cream (Example 5) Water 2.3 4.3 1.6 4.2 11 Flowing paraffin 20% cream (Comparative Example 1) SLS 8.9 10.0 6.9 5.1 12 Flowing paraffin 20% cream (Comparative Example 1) Water 0.6 2.9 0.2 3.5 13 Squalene 10% cream (Comparative Example 4) SLS 9.1 7.7 9.5 6.9 14 Squalene 10% cream (Comparative Example 4) Water 1.8 4.4 0.7 3.4 15 Flow paraffin 10% cream (Comparative Example 3) SLS 8.0 7.2 8.3 5.9 16 Flow paraffin 10% cream (Comparative Example 3) Water 1.3 3.6 0.1 1.8 17 Vaseline SLS 9.4 8.1 10.2 5.9 18 Vaseline water 1.4 3.9 1.3 3.1 19 No coating SLS 11.8 8.2 15.8 7.8 20 No coating water 0.4 3.6 0.9 3.5 200815042 13. Summary of the experiment In the case of the osmotic stress-inhibiting effect of the DEG-DA5 and the DEG-DA5-containing cream, 20 subjects with atopic dermatitis and sebum deficiency were examined. As a result, it was found that DEG-DA5 and DEG-containing cream have a tendency to suppress SLS stimulation depending on the concentration, and show the concentration at which the effect can be exerted when used in humans. _ _ According to the 24-hour close-fitting test, it is possible to confirm the safety of DEG-DA5 and patients with dermatitis and DE Lin-M5 Weishuang. _ The above results can be transferred to the recorded material mixed with DEG-DA5, which is very suitable for patients with heterozygous skin and patients with poor isolation. BRIEF DESCRIPTION OF THE DRAWINGS Fig. 1 shows the survival rate of a cream that does not contain lauryl sulphate and is exposed to cells at various concentrations. Figure 2 is a graph showing the survival rate of a cream containing 0.1% sodium lauryl sulfate at various concentrations when exposed to cells. Fig. 3 is the sum of the subjects whose scores indicate 3, 4 after the judgment of 24 hours. Figure 4 is the sum of the subjects whose scores indicate 3, 4 after 48 hours of judgment. Fig. 5 is the average value of the transepidermal water evapotranspiration after 24 hours of attachment (average s D.). Figure 6 is the average value of the transepidermal water evapotranspiration after 48 h of attachment (average health.d.). 41 200815042 [Description of main component symbols]

Claims (1)

200815042 十、申請專利範圍: 1. -種含有二聚亞油酸二乙二_旨寡聚物的化妝料。 2. 如申=範圍第1項所述之化祕,其賴高油酸二乙 -二_旨券:物中,構成之二聚亞油酸及二乙二醇的比例為,二聚 -亞油酸:二乙二醇=〇. 5莫耳:h 〇莫耳〜〇. 8莫耳:U莫耳。 3. 如申請專利範圍第1項所述之化妝料’其特徵為二聚亞油酸二乙 二醇醋寡聚物中’構成之二聚亞油酸及二乙二醇的比例為,二聚 φ 亞油酸:二乙二醇=0· 5莫耳:1· 〇莫耳。 4·如中請專繼卿1項所述之化妝料,其特徵為二聚亞油酸二乙 二酵酯寡聚物在25°C中的黏度為2, 500〜4, 500mPa · s。 5·如申請專利範圍第1至第4項中任一項所述之化妝料,其特徵為 二聚亞油酸二乙二醇酯寡聚物是一種皮膚刺激缓和成分。 6·如申請專利範圍弟1至第5項中任一項所述之化妝料,其特徵為 其是臉部用或身體用之保濕化妝料。 φ 了·如申請專利範圍第2至第6項中任一項所述之化妝料,其特徵為 其含有5〜20質量%的二聚亞油酸二乙二醇酯寡聚物。 8广種含有二聚亞油酸二乙二醇酯寡聚物的化妝料用油劑’其構成 之二聚亞油酸及二乙二醇的比例為,二聚亞油酸··二乙二醇=〇· 5 莫耳:1.0莫耳〜〇·8莫耳:1·〇莫耳。 43200815042 X. Patent application scope: 1. A cosmetic containing dimerized linoleic acid diethyl acrylate. 2. As stated in the claim 1 of the scope=Scope, the ratio of the dimerized linoleic acid and diethylene glycol in the high oleic acid di-di- keel: dimerization- Linoleic acid: diethylene glycol = 〇. 5 moles: h 〇 Mo Er ~ 〇. 8 Mo Er: U Moer. 3. The proportion of the dimerized linoleic acid and diethylene glycol formed in the dimeric linoleic acid diethylene glycol vinegar oligomer as described in claim 1 of the patent application scope is Poly φ linoleic acid: diethylene glycol = 0.5 m molar: 1 · 〇 Mo Er. 4. The cosmetic material described in the above-mentioned article is characterized in that the viscosity of the dimerized linoleic acid diacetate oligomer at 25 ° C is 2,500 to 4,500 mPa · s. The cosmetic according to any one of claims 1 to 4, wherein the dimerized linoleic acid diethylene glycol ester oligomer is a skin irritation mitigating component. The cosmetic according to any one of claims 1 to 5, which is characterized in that it is a moisturizing cosmetic for face or body. The cosmetic according to any one of claims 2 to 6, which is characterized in that it contains 5 to 20% by mass of a dimerized linoleic acid diethylene glycol ester oligomer. 8 A wide range of cosmetic oils containing diethylene linoleate diethylene glycol oligomers. The ratio of dimerized linoleic acid and diethylene glycol is dimerized linoleic acid · · · Glycol = 〇 · 5 Moule: 1.0 Mo Er ~ 〇 · 8 Mo Er: 1 · 〇 Mo Er. 43
TW096112802A 2006-05-23 2007-04-12 Cosmetics containing diethylene glycol diol diol TWI392518B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2006142943 2006-05-23

Publications (2)

Publication Number Publication Date
TW200815042A true TW200815042A (en) 2008-04-01
TWI392518B TWI392518B (en) 2013-04-11

Family

ID=38723153

Family Applications (1)

Application Number Title Priority Date Filing Date
TW096112802A TWI392518B (en) 2006-05-23 2007-04-12 Cosmetics containing diethylene glycol diol diol

Country Status (6)

Country Link
JP (1) JP4288306B2 (en)
KR (1) KR101368102B1 (en)
CN (1) CN101410088B (en)
HK (1) HK1126144A1 (en)
TW (1) TWI392518B (en)
WO (1) WO2007135841A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4747075B2 (en) * 2006-11-01 2011-08-10 日本エマルジョン株式会社 Cosmetics and external preparations
JP5137786B2 (en) * 2007-11-21 2013-02-06 株式会社ファンケル Cleansing cosmetic containing dimer dilinoleic acid diethylene glycol oligomer ester
JP5649815B2 (en) * 2009-12-21 2015-01-07 花王株式会社 Skin preparation
JP5253490B2 (en) * 2010-12-27 2013-07-31 日本エマルジョン株式会社 Cosmetics for cleaning
JP6189709B2 (en) * 2013-10-22 2017-08-30 株式会社ファンケル Itching inhibitor
JP7029235B2 (en) * 2017-06-30 2022-03-03 ポーラ化成工業株式会社 Oily cosmetics

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6780209B1 (en) * 2000-01-24 2004-08-24 The Lubrizol Corporation Partially dehydrated reaction product process for making same, and emulsion containing same
JP2004277285A (en) * 2003-01-20 2004-10-07 Nippon Fine Chem Co Ltd Cosmetic and composition for producing cosmetic
JP4331584B2 (en) * 2003-02-04 2009-09-16 日本精化株式会社 Oily base and cosmetics and skin external preparations containing the same

Also Published As

Publication number Publication date
KR101368102B1 (en) 2014-02-27
JP4288306B2 (en) 2009-07-01
HK1126144A1 (en) 2009-08-28
TWI392518B (en) 2013-04-11
CN101410088A (en) 2009-04-15
JPWO2007135841A1 (en) 2009-10-01
WO2007135841A1 (en) 2007-11-29
KR20090014143A (en) 2009-02-06
CN101410088B (en) 2011-06-22

Similar Documents

Publication Publication Date Title
TWI607764B (en) External dermal composition for anti-ageing and method for producing the same
US7994141B2 (en) Compositions comprising compounds of natural origin for damaged skin
CN104000752A (en) Ginger extract for the protection of stem cells
JP2021533079A (en) Skin care composition for skin repair and its preparation method
JP2019116484A (en) Method of transdermally absorbing hydrophilic drug
JP2012041302A (en) Skin cosmetic
JP2012502020A (en) Cosmetic composition comprising polyhydroxylate (POLYHYDROXYLTATE) fatty alcohol and derivatives and uses thereof
TW200815042A (en) Cosmetic preparation containing dimer dilinoleic acid diethylene glycol oligomer ester
CN113081903A (en) Transparent whitening essence containing 4-butylresorcinol and preparation method thereof
JP4088497B2 (en) Cosmetics
JP2003113040A (en) Antibacterial cosmetic composition
JP5318395B2 (en) Oily composition containing dimer dilinoleic acid diethylene glycol oligomer ester
JP2019189556A (en) Phosphatidylinositol-containing complex
JP5225655B2 (en) Dimerized linoleic acid diethylene glycol oligomer ester-containing emulsion composition
JP2007314427A (en) Lipoic acid-containing complex
JP5225654B2 (en) Dimerized linoleic acid diethylene glycol oligomer ester-containing emulsion composition
WO2009085236A2 (en) Compositions and methods of using substance p. analogs
JP5137786B2 (en) Cleansing cosmetic containing dimer dilinoleic acid diethylene glycol oligomer ester
JP2004010505A (en) Cosmetic
JP4365281B2 (en) DFA-containing external preparation for skin, cosmetics, ophthalmic solution
JP6862176B2 (en) Emulsified composition
JP2022166655A (en) Skin cosmetic
JP2023007524A (en) Permeation enhancing material
WO2017045570A1 (en) Skincare composition containing polysiloxane